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The mechanism of toxic action for organophosphates (OPs), originally developed
as insecticides, is the persistent inhibition of acetylcholinesterase (AChE) resulting in
accumulation of acetylcholine and subsequent hyperstimulation of the nervous system.
Many OPs require bioactivation via cytochromes P450 to oxon metabolites which are
anticholinesterases. Organophosphates display a wide range of acute toxicities.
Differences in the OPs’ chemistries results in differences in the compounds' metabolism
and toxicity. Acute toxicities of OPs appear to be principally dependent on compound
specific efficiencies of detoxication, and less dependent upon efficiencies of bioactivation
and sensitivity of AChE. Esterases, such as carboxylesterase (CaE) and
butyrylcholinesterase (BChE), play a prominent role in OP detoxication.
Organophosphates can stoichiometrically inhibit these enzymes, removing OPs from
circulation thus providing protection for the target enzyme, AChE. This in vitro study
investigated: 1) age-related sensitivity of AChE, BChE and CaE to structurally different
OPs in rat tissues; 2) interspecies and intraspecies differences in bioactivation and
detoxication of the OP insecticide malathion in rat and human hepatic microsomes; and

3) interspecies and intraspecies differences in sensitivity of AChE from erythrocyte ghost
preparations to malaoxon. Sensitivities of esterases to 12 OPs was assessed by IC50s. The
OPs displayed a wide range of AChE IC50s (low nM-µM) with no differences among
ages; however, the CaE IC50s generally increased with age (up to 100-fold) reflecting
greater protection in adults. Kinetic analysis of the bioactivation of malathion to the
anticholinesterase metabolite, malaoxon, was measured in hepatic microsomes from rats
(adult) and humans (various ages) of both sexes. No statistical interspecies (rat and
human) or intraspecies (among humans) differences were found. The CaE degradation of
malathion and malaoxon was determined in the microsomal samples using indirect
measurements. No interspecies or intraspecies differences were found; however, CaE
activity in rat microsomes was significantly higher than in humans. Inhibition of AChE
by malaoxon was analyzed kinetically in erythrocyte ghost preparations from rats (adults)
and humans (three age groups) of both sexes. No statistical interspecies or intraspecies
differences were found. These results suggest the age-related differences in acute
toxicities of OPs in mammals is primarily a result of their detoxication capacity.
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CHAPTER I
INTRODUCTION
History and Usage of Organophosphates
Organophosphates (OPs) were first synthesized in the 1800s. A French chemist,
Philippe de Clermont, reported the synthesis of the first known OP acetylcholinesterase
inhibitor, tetraethylpyrophosphate, at a meeting of the French Academy of Sciences in
1854 (Fest and Schmidt, 1982). This class of compounds were named organophosphates
for the central phosphorus element in their structure. In 1932, German chemists Willy
Lange and Gerduh von Krueger were the first to describe the effects of OPs on the
nervous system after observing that OP exposure resulted in pupil constriction, increased
light sensitivity, and respiratory distress. Organophosphorus compounds were initially
developed as insecticides by German chemists, led by Gerhard Schrader, in the late
1930s. Many of these OPs were found to be extremely toxic. According to German
(Nazi) law at the time, all research discoveries with potential warfare applications were
required to be reported to the government (Johnson et al., 2015). While working on
developing insecticides for the chemical company, IG Farben, Schrader synthesized a
highly toxic OP which he named “tabun” (Hersh, 1968; Hammon, 1994). Due to the
observed toxicity and volatility of some of the OPs Schrader synthesized, he was ordered
to develop them into chemical weapons in the lead up to WWII (Coleman, 2005; Tucker
2007). These so called “nerve gases” are more correctly termed “nerve agents” as they
1

are actually liquids that can be aerosolized and include the G agents and V agents. The G
agents were developed in Germany and include sarin, soman, and tabun. The V agents,
including VX, were initially developed by the British and later produced in the United
States (VX) and the Soviet Union (VR). The G and V agents are both very potent
anticholinesterases with the major difference being the G agents are faster acting while
the V agents are much more persistent (Coleman, 2005; Johnson et al., 2015). Although
these very potent OPs were stockpiled for chemical warfare during WWII, fortunately,
the deployment of these toxic agents was limited.
In the 1940s and 1950s, the most heavily used insecticides were organochlorines
(Ecobichon, 1991). These chlorinated compounds, though highly effective, were
environmentally persistent and could bioaccumulate in wildlife and humans (Hickey and
Anderson, 1968; Schmitt, 2002; Li et al., 2006). The deleterious effects of the
organochlorines in wildlife populations as well as increasing insect resistance spurred the
research and development of OP insecticides following WWII. The OPs, being potent
insecticides and more environmentally labile than the organochlorines, began gaining
popularity in the insecticide market during the late 1950s and early 1960s (Hayes and
Laws, 1991). Tetraethylpyrophosphate (TEPP) was the first commercially available OP
insecticide; however due to its extreme toxicity and chemical instability, it was not
heavily used (Ecobichon, 1996). As the class of OP compounds began expanding, one of
the most popular OPs, parathion (O,O-diethyl-O-4-nitrophenyl phosphorothionate), was
developed and used as an insecticide for many years, despite its high mammalian toxicity
(Hayes and Laws, 1991; US EPA, 2000; ATSDR, 2017). Several cases of poisoning of
2

factory and agricultural workers occupationally exposed to parathion stimulated the
development of analogs that were less toxic to non-target species, wildlife and humans,
and more selective for the target insect species (Hayes and Laws, 1991). The use of OPs
in the United States became increasingly popular with the banning of organochlorines,
such as DDT, in 1972 (Dunlap, 1981). Chlorpyrifos, [O,O-diethyl-O-(3,5,6-trichloro-2pyridyl) phosphorothionate], an OP with moderate mammalian toxicity, was developed
and registered in 1965 and has been used extensively in both agricultural and residential
applications (US EPA, 2002; ATSDR, 2017). Malathion (O,O-dimethyl dithiophosphate
of diethyl mercaptosuccinate), was developed in the early 1950s and is still one of the
most heavily used OP insecticides due to its effectiveness as an insecticide and its very
low mammalian toxicity (Meister, 1992; US EPA, 2006; ATSDR, 2017). Other OP
insecticides that have been heavily used in the United States and throughout the world
include diazinon, azinphos-methyl, dichlorvos, and methyl parathion (Hayes and Laws,
1991). The insecticidal applications for these and many other OPs include both
agricultural and residential pest control (Matsumura, 1985; Hayes and Laws, 1991;
Meister, 1992). In addition, OPs have been developed that have applications as
fungicides, herbicides, defoliants, and flame retardants, which are not designed as
anticholinesterases.
Due to the high usage of OP insecticides worldwide, the possibility of human
exposure and subsequent intoxication remains a concern. Though both agricultural and
residential applications have recently been restricted, especially in the United States (US
EPA, 2011), the possibility of acute or chronic exposures still exist. Occupational
3

exposures to formulators and applicators offer the greatest likelihood of high acute
exposures (Ware et al., 1973), while exposure to the general population is more likely to
be lower in level, may be acute or chronic, and typically occur through ingestion of OP
residues on food or from residential pest control (Simcox et al., 1995; Davis and Ahmed,
1998; Duggan et al., 2003). In 1993, the National Research Council produced a report
titled “Pesticides in the Diets of Infants and Children” which raised concerns that
children may be exposed to greater levels of pesticides due to their diet and greater food
intake per unit body weight (NRC, 1993). This report was a driving force behind the
passing of the Food Quality Protection Act (FQPA) in 1996. FQPA mandated that
consideration must be given for vulnerable populations (children) in risk assessments for
pesticides and, if necessary, an extra safety factor (up to 10x) must be included (Duggan
et al., 2002). A child’s behavior can also result in an increased risk of exposure via
crawling on contaminated floors and placing fingers or hands in or around his or her
mouth (Gurunathan, et al., 1998). The developmental process in humans is an elaborate
highly coordinated cascade of processes that must occur in critical periods and is
vulnerable to toxic insults. Any alteration or deviation from the normal processes of
maturation can lead to pathological or behavioral aberrations immediately or later in life
(Karczmar, 1984; West, 2002). The developing nervous system may be particularly
vulnerable to toxic insults that may lead to long-term neurological damage (Selevan et
al., 2000; West, 2002). Since the mode of action of many insecticides, including the
OPs, is to attack the nervous system of an insect, the effects on the nervous system of
non-target species is a logical concern, especially during developmental critical periods
4

(Karczmar, 1984). The sensitivity of immature animals to many OP insecticides has been
well documented in rodents (Brodeur and DuBois, 1963; Benke and Murphy, 1975;
Gaines and Linder, 1986; Pope et al., 1991, Moser et al., 1996; Atterberry et al., 1997).
Although the use of OP pesticides, especially in the United States, has been
restricted, the relative low cost of these highly effective insecticides makes their use still
prevalent in developing countries. In some cases, particularly in developing countries,
OPs have been used to commit suicides (Eddleston, 2000, Buckley et al., 2004, Pandit et
al., 2011). In addition, the possibility of exposure to OP nerve agents such as sarin,
soman and VX still exists in warfare and terrorist attacks. The relative ease and low cost
of synthesis of these types of nerve agents make them popular chemical weapons among
rogue nations and terrorist groups (Tucker, 2007; Johnson et al., 2015). Although the
Chemical Weapons Convention of 1993 outlawed the production and stockpiling of any
chemical weapons, there are still stockpiles of these highly potent nerve agents in many
countries, including the United States (Smart, 1997; Tucker, 2007; Johnson et al., 2015).
During the Iran-Iraq War, Iraqi forces unleashed sarin on Iranian forces killing over 4000
soldiers and civilians (Rose and Baravi, 1988; Balali-Mood and Balali-Mood, 2008). In
the late 1980s, Sadam Houssain ordered Iraqi troops to release sarin on Kurdish civilians
in northern Iraq, killing and injuring thousands (Smart, 1997). More recently, sarin has
been used several times by the Syrian regime killing several thousand rebels and
civilians, including many children (Dolgin, 2013; Pita and Domingo, 2014; Rosman,
Eisenkraft et al., 2014). Terrorist groups or individuals, so called “lone wolf” terrorists,
who want to cause casualties as well as mass hysteria, may look to unconventional
5

methods, such as nerve agents. In 1995, a Japanese religious sect known as Aum
Shinrikyo released sarin in the Tokyo subway system resulting in the deaths of 12 people
and over 1000 injured. Some of the injured suffered long term neurological and
behavioral deficits (Nagao et al., 1997; Yokoyama et al., 1998). In 2017, the nerve
agent, VX, was used to assassinate Kim Jong Nam, the brother of North Korean leader
Kim Jong Un, at Kuala Lumpur international airport (Bradley, 2017). Most recently, a
former Russian spy for the United Kingdom along with his daughter were poisoned with
Novichok, an extremely toxic OP nerve agent developed in Russia that is difficult to
therapeutically treat (Peplow, 2018). The ability of terrorist groups, such as ISIS, to
produce or procure these types of chemicals is of great concern. Even some of the more
potent OP insecticides are included in the chemical threat agent category (Jett, 2012).
Given the large quantities of OPs produced and the variety of applications, the potential
for human exposure is still quite high.
Organophosphorus Compound Structure and Potency
Organophosphorus insecticides are a large family of compounds that are named
for their central phosphorus atom. Most OPs are esters of pentavalent phosphorous acids
that have a variety of side chains termed “leaving groups.” This chemical family
includes phosphates, phosphorothionates, and phosphorothionothiolates (Chambers,
1992). The phosphates (P=O) include compounds such as dichlorvos and naled. These
compounds are active anticholinesterases and thus do not require bioactivation. The
phosphorothionates (P=S) include the widely used insecticides chlorpyrifos, parathion,
methyl parathion, and diazinon. The phosphorothionothiolates (P=S) include the
6

insecticides malathion and azinphosmethyl. The phosphorothionates and
phosphorothionothiolates both require bioactivation by cytochromes P450 (CYP) to their
“oxon” metabolites, which are the more potent anticholinesterases (Kulkarni and
Hodgson, 1980; Sultatos and Murphy, 1983; Chambers and Forsyth, 1989; Chambers and
Chambers, 1989; Fukuto, 1990; Hayes and Laws, 1991; Chambers, 1992). The P=S
containing “parent” insecticides are generally not very potent anticholinesterases
(Chambers and Chambers, 1989; Fukuto, 1990). The variety of structures of OPs
produces a varied amount of potency both in the target species, insects, and non-target
species, such as mammals (including humans) (Holmstedt, 1963; Fukuto, 1990; Hayes
and Laws, 1991; Chambers, 1992). The US EPA human hazard classification consists of
four levels (US EPA, 2004) and the OPs cover all four of these levels. Rat oral lethal
dose 50 (LD50) levels in mammals range from a very low mg/kg level (e.g., parathion, 313 mg/kg) to a high mg/kg level (e.g., malathion, 1,000-12,500 mg/kg) (Hayes and Laws,
1991; Meister, 1992). EPA class I compounds are classified as the greatest hazard and
about one-half of the OPs fall into this classification (Meister, 1992).
There are several factors that affect the bioavailability and toxicity of an OP.
These factors include absorption, distribution, metabolism, excretion and the sensitivity
of the target enzyme, acetylcholinesterase (Mileson et al., 1998; Timchalk et al, 2002).
All of these factors are dependent on the structure of the OP. The more lipophilic OPs
are often more easily absorbed and distributed (Garcia-Repetto et al., 1995; Chambers
and Carr, 1993; Mileson et al., 1998). Once absorbed, the OPs can be transported to the
liver where the phosphorothionates and phosphorothionothiolates can be bioactivated by
7

oxidation (desulfuration) via CYPs (O’Brien, 1062) to their oxon metabolites
(anticholinesterase) (Murphy and DuBois, 1957; Nakatsugawa and Dahm, 1967, Sultatos
et al., 1980; Forsyth and Chambers, 1989).
CYPs are heme-containing proteins with the heme iron usually in the ferric state.
CYPs are found in most tissues with a high concentration located in the mitochondria and
endoplasmic reticulum (microsomes) in livers of mammals (Guengerich, 1987). The
CYP family consists of many different isoforms that have a variety of substrate
specificities. CYPs are involved in the biosynthesis and catabolism of bile acids, steroid
hormones, fatty acids, and fat soluble vitamins. In addition, CYPs mediate a variety of
chemical reactions with xenobiotics including hydroxylations, dealkylations,
epoxidations and oxidations (Guengerich, 1987). These reactions mediated by CYPs can
result in both activation and detoxication of many xenobiotics. The activation of some
xenobiotics, such as some OPs and environmental pollutants, to more biologically active
metabolites, may result in toxicity (Kulkarni and Hodgson, 1980). CYPs are inducible by
a variety of compounds including persistent organic pollutants (polychlorinated biphenyls
and some organochlorine pesticides), pharmaceuticals (e.g., phenobarbital), and some
carcinogens (Menzer and Best, 1968; Johnson, 1980; Guengerich, 1987). In addition to
the CYP mono-oxygenase system, some OPs, such as disulfoton and phorate, can
undergo oxidations via FAD-containing mono-oxygenases (FMOs) which are also
present in substantial amounts in hepatic microsomes (Levi and Hodgson, 1988; Mileson
et al., 1998).
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The CYP mediated oxidations (desulfuration) reaction rates for OPs differ
depending on CYP isozyme concentrations and OP structures (Ma and Chambers, 1995;
Buratti et al., 2005). CYP mediated detoxication of some OPs, such as parathion, may
also occur via oxidative cleavage (dearylation) yielding p-nitrophenol and
diethylphoshorothioic acid (Ma and Chambers, 1994; Chambers and Carr, 1995;
Timchalk, 2001). The desulfuration and dearylation are thought to result from the same
phosphooxythiiran intermediate (Neal, 1980). The percentage of OP compound
undergoing desulfuration (activation) compared to dearylation (detoxication) is
dependent on the CYP isozymes present and will affect the amount of oxon produced
resulting in toxicity (Levi and Hodgson, 1985; Timchalk, 2001; Buratti et al., 2005).
Organophosphate Mechanism of Toxic Action
Organophosphates can interact with a variety of enzymes, but their primary toxic
action is due to inhibition of acetylcholinesterase (AChE) (Ecobichon, 1996; Mileson et
al., 1998). The physiological function of AChE is to hydrolyze the neurotransmitter
acetylcholine (ACh) in the cholinergic system (Watanabe et al., 1990). ACh is
synthesized in a neuronal cell from a process in which pyruvate, from glycolysis, is
converted to acetyl coenzyme A (acetyl CoA). Subsequently, acetyl CoA is combined
with choline via the enzyme choline acetyltransferase, to form the neurotransmitter ACh.
The resulting ACh is packaged and stored in vesicles for release into the synapse upon
electrical stimulation by a nerve impulse (Taylor, 1990; Fukuto, 1990; Ecobichon, 1996).
Once released into the synaptic cleft, ACh binds receptors on the adjacent nerve or
effector cell triggering a subsequent electrical impulse. Stimulation of the cholinergic
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system continues as long as ACh levels remain sufficient in the synapse or
neuromuscular junction. To prevent overstimulation of the cholinergic system, the
enzyme AChE cleaves ACh into acetate and choline. Choline is recycled back into the
presynaptic nerve terminal via a choline transporter (Taylor, 1990; Fukuto, 1990; Purves,
2001; Thompson and Richardson, 2004).
OP oxons can inhibit AChE by phosphylating the serine hydroxyl group at the
catalytic center or “gorge” of the enzyme; this persistent phosphorylation (inhibition)
results in a loss of enzymatic activity (Fukuto, 1990; Chambers, 1992; Mileson et al.,
1998). Inhibition of AChE results in the accumulation of ACh within the cholinergic
synapses and neuromuscular junctions, leading to hyperactivity of the cholinergic system
(Fukuto, 1990; Mileson et al., 1998). The elevation of ACh levels results in the
excessive stimulation of both muscarinic and nicotinic ACh receptors (Wiener and
Taylor, 1990; Fukuto, 1990). Muscarinic acetylcholine receptors (mAChR) function both
pre- and post-synaptically and are involved in both the peripheral and central nervous
systems. There are several subtypes of mAChRs and, depending upon the subtype,
overstimulation from elevated ACh can produce a myriad of effects including involuntary
salivation, lacrimation, urination, and defecation (SLUD). Overstimulation of nicotinic
receptors in both the sympathetic and parasympathetic nervous systems in mammals can
result in muscle fasciculation, tremors, convulsions, and paralysis. Bradycardia and
tachycardia can both occur depending upon the balance between overstimulation of the
parasympathetic and sympathetic cholinergic system (Taylor, 1990). Excessive secretion
of mucus in the airway disrupts the flow of oxygen inducing respiratory distress. In the
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CNS, overstimulation of the cholinergic system, involving both muscarinic and nicotinic
receptors, can result in memory loss, restlessness, lethargy, confusion, and effects on
respiratory control centers (Taylor, 1990; Ecobichon, 1996). In cases of severe OP
intoxication, somatic muscles undergo fatigue and ultimately paralysis. The resulting
paralysis of the diaphragm and intercostal muscles in conjunction with excessive mucus
secretions lead to respiratory failure and ultimately death (Thompson and Richardson,
2004).
Organophosphate Toxicity Signs and Treatment
Exposure to organophosphates can result in a variety of toxic signs and
symptoms. The severity of the toxicity depends on the OP and level of exposure. The
cholinergic toxidrome associated with organophosphate exposure includes central
nervous system responses such as miosis, headache, restlessness, convulsions, loss of
consciousness, and coma. The respiratory system can be affected resulting in rhinorrhea,
bronchorrhea, wheezing, dyspnea, chest tightness, hyperpnea, and bradypnea. Cardiac
effects of OP exposure can result in tachycardia, bradycardia, other arrhythmias,
hypertension and hypotension arrhythmias. OP exposure can also affect the GI tract
causing abdominal pain, nausea, vomiting, and diarrhea. The musculoskeletal system can
be affected resulting in weakness and fasciculation. Other signs and symptoms of OP
exposure include lacrimation, excessive sweating, and urinary incontinence. If exposure
is severe death can occur through respiratory depression (Taylor, 1990; Mileson et al.,
1998; Bajgar, 2004).
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If exposure to OPs is known or suspected, blood tests can be performed to assess
cholinesterase activity. Erythrocyte AChE activity or plasma butyrylcholinesterase
(BChE) activity can be measured and compared to a normal (average) activity range
(Bajgar 2004, Worek et al., 2005; 2016; Eddleson et al., 2008). AChE has been
determined to be a single gene product (Taylor et al., 1993); therefore, erythrocyte AChE
inhibition should reflect (biomarker) AChE inhibition in the CNS, the ultimate target of
concern (Chen et al., 1999; Eddleston et al., 2008). Butyrylcholinesterase activity may
also be used as a biomarker of OP exposure and is commonly measured by clinical
chemistry analyzers (van Heel and Hachimi-Idrissi, 2011; Worek et al., 2005; Schilha et
al,. 2016). If AChE or BChE activity is decreased, suggesting OP exposure, testing for
metabolites in the blood may be necessary to confirm OP exposure. Patient history, such
as occupation or recent residential pesticide treatment, may help confirm the type of
exposure. For example, an agricultural worker or exterminator, may provide information
as to the insecticide they have been applying, thus the likely source of exposure. If signs
of OP exposure are severe, especially in the case of nerve agents or industrial accidents,
where death could occur quickly, immediate treatment may begin prior to confirmation of
exposure (Bajgar, 2004; Eddleston et al., 2008).
The typical treatment following an exposure to an OP includes the administration
of the muscarinic receptor antagonist, atropine, to temporarily block the effects of the
accumulation of ACh and an oxime such as 2-pyridine aldoxime methyl chloride
(commonly called 2-PAM or pralidoxime) to reactivate inhibited AChE (Kassa, 2002;
Bajgar, 2004; Smythies and Golomb, 2004). Oximes, such as 2-PAM, reactivate AChE
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by nucleophilically attacking the phosphorus of the OP covalently bound to the enzyme
and removing the phosphyl moiety (Bajgar, 2004). Once reactivated, AChE is able to
function normally and hydrolyze its endogenous substrate, ACh. Reactivation of OP
inhibited AChE must occur prior to the enzyme “aging”, a process in which the OP
covalently bound to AChE is dealkylated (Beauregard et al., 1981; Wilson et al., 1992).
The dealkylation of the bound OP stabilizes the enzyme-OP complex preventing
spontaneous or chemically induced reactivation. The rate of aging primarily depends on
the steric orientation of the OP in the active site of AChE and the side chains of the OP
(Bošković et al., 1968; Carr and Chambers, 1996). Reactivation of OP inhibited AChE
can spontaneously occur; however, this process is usually very slow and depends on the
structure of the OP (Clothier et al., 1981; Wilson et al., 1992). Once the OP-enzyme
complex has aged the only way to compensate for the loss of enzyme activity is de novo
synthesis of AChE molecules (Thompson and Richardson, 2004), which has been shown
to take 2-24 hours with complete recovery to normal activity taking 80-100 days
(Rotundo and Fambrough 1980). The loss of AChE activity to aging may increase the
susceptibility of the organism to subsequent OP exposures.
In cases of high level OP exposures such as industrial accidents or nerve agent
attacks, CNS seizures may be induced. Treatment for OP induced seizures will typically
include a benzodiazepine such as diazepam or midazolam (Marrs, 2003; Shih et al.,
2003). The use of a benzodiazepine will bind gamma-aminobutyric acid (GABA)
receptors producing a conformational change which activates chloride ion channels
resulting in an influx of chloride ions to hyperpolarize the neuronal cell. The
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hyperpolarization diminishes the electrical signals and thereby dampens seizure activity.
OP induced seizures have been shown to produce neuroinflammation, neuropathology,
and long term neurological behavioral deficits (Marrs, 2003; McDonough and Shih,
1997; Shih et al., 2003). A major limitation of the current treatment paradigm for severe
OP exposure is the inability of the currently approved oxime therapeutics to cross the
blood-brain barrier and reactivate OP inhibited AChE in the CNS. The inability to
reactivate AChE in the brain may result in long term damage and cognitive dysfunction
(Chambers et al., 2013). Ultimately, the toxicity of a given OP is determined by the
sensitivity of the target enzyme, AChE, to the OP as well as the OP detoxication capacity
of the organism (Mileson et al., 1998). The major detoxication enzymes for the OPs
included both A-esterases and B-esterases. A-esterases are enzymes which can detoxify
OP oxon molecules via catalytic hydrolysis. B-esterases, of which AChE is a member,
include both carboxylesterases (CaE) and butyrylcholinesterase that stoichiometrically
detoxify OP oxons (Aldridge, 1953; Maxwell, 1992; Chambers, 1992; Atterberry et al.,
1997; Moser et al., 1998). These enzymes systems will be described in greater detail in
the following sections.
Acetylcholinesterase
Acetylcholinesterase (AChE; EC 3.1.1.7) is a serine esterase that hydrolyzes its
endogenous substrate acetylcholine (ACh) into its chemical components, acetic acid and
choline. The hydrolysis of ACh terminates its function as a neurotransmitter (Taylor,
1990; Fukuto, 1990; Tripathi, 2008). AChE is one of the most efficient and fastest
enzymes in the mammalian system, capable of hydrolyzing 10 to 25 thousand ACh
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molecules of acetylcholine per second (Wilson and Harrison, 1961; Taylor and Radic,
1994). The catalytic (esteratic) gorge of AChE consists of a triad of residues; serine 203,
glutamate 334 and histidine 447 (Tripathi, 2008). The enzyme also contains a secondary
binding site (peripheral anionic site) which can alter catalytic activity through binding
inhibitors preventing endogenous substrate binding in the catalytic center (Fukuto, 1990;
Tripathi, 2008). The esteratic and anionic sites are both involved in the binding of ACh
with the quaternary nitrogen of ACh interacting with the peripheral anionic site helping
to orient the carbonyl group into the esteratic (active) site (Fukuto, 1990; Taylor and
Brown, 1999). The enzyme AChE in mammals is believed to be encoded by a single
gene product with alternative mRNA processing and post-translational modification
giving rise to soluble and membrane-bound forms in various tissues (Taylor et al., 1993;
Massoulié et al., 2008).
The three forms of AChE consist of a synaptic form (AChE-S, also known as the
T (tail) form, found in brain and muscle) (Massoulié et al., 2008; Fisher and Wonnacott,
2012), a readthrough form (AChE-R found in embryonic and tumor cells), and an
erythrocytic form (AChE-E, also known as the H (hydrophobic) form, found anchored to
erythrocyte membranes) (Bartels et al., 1993; Massoulié et al., 2008). Synaptic AChE-S
is multimeric and membrane-bound (Seidman et al., 1995). Readthrough AChE-R
consists of soluble monomers (Karpel et al., 1994; 1996; Dori et al., 2007) and may be
induced in response to psychological stress or AChE inhibition (Kaufer et al., 1998). Its
endogenous function is not well understood, but recent work indicates that it may play an
anti-apoptotic role following certain forms of cellular stress and its expression may be
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increased in Alzheimer’s disease (Campanari et al., 2016; Zimmermann, 2013).
Erythrocytic AChE-E is dimeric and is anchored to the erythrocyte cell membrane by
glycosylphosphatidyl inositol, a lipid moiety. Cysteine residues in synaptic and
erythrocytic AChE allow them to exist as multimers and dimers, respectively, while the
monomeric form of the readthrough AChE-R is devoid of cysteine residues (Li et al.,
1991). Although the differences in endogenous function of the three different molecular
forms is not completely understood, their catalytic properties are conserved (Schwarz et
al., 1995; Taylor et al., 1993; Grisaru et al., 1999; Massoulié et al., 2008).
The fact that the catalytic domains of brain and erythrocyte AChE are identical
within a given species suggests that their interactions with inhibitors would be similar
(Herkert et al., 2012). This has given rise to the use of erythrocyte AChE activity as a
surrogate for brain AChE inhibition and therefore a biomarker of OP exposure (Chen et
al., 1999). The sequence homology (about 90%) of the catalytic domains of human and
rat AChE (Wiesner et al., 2008; Uniprot, 2017a, 2017b), though not identical, makes the
rat a logical choice for testing OP inhibition for extrapolation to humans. Studies have
shown some small effects of both age and sex on AChE pharmacodynamics in rodents
(Ecobichon and Stephens, 1972; Tang et al., 2003). AChE activity has been shown to
increase from birth to weaning in rats with some small differences in sex (Tang et al.,
2003; Timchalk et al., 2007). Differences in AChE sensitivities to OPs in brains of adult
and juvenile rodents do not account for age-related differences in OP toxicity (Benke and
Murphy, 1975; Pope et al., 1991; Mortensen et al., 1996; Moser et al., 1996; Atterberry
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et al., 1997), providing more evidence that AChE activity matures quickly during
development.
Drugs have been designed and approved to target AChE in the treatment of some
diseases. Reversible AChE inhibitors have been used in the treatment of myasthenia
gravis and glaucoma (Taylor, 1990). AChE inhibitors (reversible), such as tacrine, have
been used in the treatment of Alzheimer’s disease by increasing cholinergic
neurotransmission and function (Camps et al., 2000). In addition, reversible inhibitors,
such as the carbamate, pyridostigmine bromide, have been used by warfighters as
prophylactics in anticipation of encounters with nerve agent (Marino et al., 1998). AChE
also functions prominently in neural development in cell proliferation and differentiation
(Layer and Willbold, 1995). AChE aids in the outgrowth of neurites (extensions of the
axon at the ends of which are synapses), neuronal proliferation and migration, and axonal
outgrowth (Sharma et al., 2001).
Butyrylcholinesterase
Butyrylcholinesterase (BChE; EC 3.1.1.8) is a serine esterase synthesized in the
liver and is found in several other tissues including lung, heart, brain, and skeletal muscle
but is ubiquitous in the serum (Chatonnet and Lockridge, 1989; Li et al., 2000; Kolarich
et al., 2008). BChE is often referred to as pseudocholinesterase or plasma cholinesterase
and interacts with many different choline esters making it a non-specific cholinesterase,
but it does not appear to be necessary for survival (Primo-Parmo et al., 1996; Li et al.,
2000). BChE is similar to AChE in that both are glycoproteins containing both an
esteratic binding site (central catalytic site) consisting of the same catalytic triad or
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residues and an anionic binding site (peripheral binging site) (Masson et al., 1993, 1997;
Reiner et al., 1996; Lockridge et al., 1997; Simeon-Rudolf et al., 1999). The true
endogenous function of BChE is not well understood; however, it does have the ability to
hydrolyze acetylcholine and a variety of exogenous substrates including butyrylcholine,
mivacurium, succinylcholine, aspirin, heroin, cocaine, and organophosphate oxons (Cook
et al., 1989; Fukuto, 1990; Sparks et al., 1999; Li et al., 2000; Carmona et al., 2000; Hou
et al., 2014).
Cholinesterase activity in human serum consists largely of BChE, approximately
90% (Li et al., 2000), giving rise to its use as a biomarker of OP exposure (Worek et al.,
2005). Rodents typically have a more equivalent proportion of BChE and AChE in their
serum (Li et al., 2000). This can be a confounder in extrapolating OP toxicities in animal
studies to humans, due to differences in sensitivities of BChE and AChE. Similar to
AChE, BChE is stoichiometrically inhibited by OP oxons; however, BChE inhibition
serves as an OP detoxication mechanism by reducing the bioavailable levels of the OP,
therefore reducing the amount of OP available to inhibit the target, AChE (Fukuto, 1990;
Mileson et al., 1998). As with AChE, sensitivities of BChE to OPs depends on the
structure of the OP (Worek et al., 2005).
Although BChE has been shown not to be necessary for survival, its ability to
hydrolyze ACh has been suggested to be an important physiological function in both
synapses and neuromuscular junctions in the CNS and the PNS, with BChE serving as a
backup to AChE to hydrolyze excess ACh when AChE activity has been compromised
(Li et al., 2000). BChE has been found in the neurofibrillary tangles and amyloid plaques
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in brains of victims of Alzheimer’s disease (Carson et al., 1991; Arendt et al., 1992;
Moran et al., 1993), although the role BChE may play in these pathologies is not
understood. More recently, BChE has been investigated as a potential medical
countermeasure against nerve agents by acting as a bioscavenger of OPs (Masson and
Lockridge, 2010; Nachon et al., 2013). Scavenging of nerve agent in the blood stream
prior to reaching the target enzyme, AChE, could reduce the neurotoxicity following
exposure (Raveh et al., 1993; Lenz et al., 2007). Researchers have created
“pseudocatalytic” mutants of BChE to increase their efficiency as OP bioscavengers in
the blood (Cerasoli et al., 2005).
A-esterases
A-esterases are hydrolases (Aldridge, 1953) synthesized predominantly in the
liver and are associated with high-density lipoproteins (HDL) in the serum (Mackness et
al., 1985; Zech et al., 1993). A-esterases can catalytically hydrolyze the oxons of some
OP compounds and are typically divided into two groups. The first, paraoxonase (PON;
EC 3.1.8.1), named for its ability to hydrolyze the OP, paraoxon, is a calcium dependent
hydrolase. The second group, DFPases (EC 3.1.8.2), named for their ability to hydrolyze
diisopropylfluorophosphate (DFP) are dependent on cofactors such as cobalt,
magnesium, and manganese (Aldridge, 1953). Paraoxonases are the primary A-esterases
involved in the catalytic destruction of the OP insecticides, though some are not
hydrolyzed very efficiently by PON (e.g., paraoxon, despite being named for it), or not at
all. Paraoxonase and A-esterase are often used interchangeably when referring to the
catalytic destruction of OPs. The A-esterases in the serum and liver of rats were
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determined to be the same protein using gel staining and site directed mutagenesis
(Furlong et al., 1993; Sorenson et al., 1995). The catalytic activity of these enzymes is
dependent on calcium ions, which is also involved in the stabilization of the enzyme
structure (Vitarius and Sultatos, 1995; Kuo and La Du, 1998). Thus, the use of metal
chelating agents, such as EDTA or EGTA, can inhibit the activity of paraoxonase.
Paraoxonases are a multigene family, including PON1, PON2, and PON3 (PrimoParmo et al., 1996; Hegele, 1999). With a cysteine located in the catalytic center of the
enzyme, these hydrolases are sensitive to inhibition by metallic salts (mercury, zinc,
nickel, and copper) and mercurial compounds that have affinity for sulfhydryl groups
(Aldridge, 1953; Gil et al., 1993; Gonzalvo et al., 1997).
Paraoxonases can affect the acute toxicity of several OP compounds (Costa et al.,
1990; Chambers, 1992; Chambers et al., 1994; Pond et al., 1995; Mortensen et al., 1996).
Mammals have higher levels of paraoxonase activity than most other species making
species such as some birds and fish more sensitive to the acute toxicities of some OPs.
(Machin et al., 1976; Brealey et al., 1980). Costa et al. (1990) reported that rats pretreated (injected) with purified A-esterase were less sensitive (as evidenced by
acetylcholinesterase inhibition) to paraoxon and chlorpyrifos-oxon. Li et al. (1993;
1995) reported similar findings of pre-treatment with A-esterase providing increased
protection in mice exposed to chlorpyrifos and chlorpyrifos-oxon. The development of
knockout mouse models has allowed for testing the detoxication potential of paraoxonase
for certain OPs by “knocking” out the PON1 gene, therefore eliminating its catalytic
activity (Shih et al., 1998). Furlong et al. (2000) demonstrated that the knockout
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mutation of the gene eliminated PON1 catalytic activity in both liver and plasma of mice,
further indicating that activities from these two tissues results from a single gene. Shih et
al. (1998) demonstrated that PON1 wild type mice were much less sensitive (as
evidenced by cholinesterase inhibition) to chlorpyrifos-oxon than PON1 knockout mice.
In another study, knockout mice were also more sensitive to diazoxon (a good PON1
substrate) but did not show increased sensitivity to paraoxon (a poor PON1 substrate) (Li
et al., 2000). These studies suggest that PON1 is an important detoxication pathway for
some OPs and the catalytic efficiency of PON1 for a given OP is important in
determining the level of protection provided for the target, brain acetylcholinesterase.
In humans, polymorphisms of paraoxonase have been determined that result in
differences in PON1 concentrations and activities (Humbert et al., 1993; Davies et al.,
1996). A PON1 polymorphism in an amino acid residue at position 192, a glutamate (Q)
or an arginine (R), alter PON1 OP hydrolysis activity. An R isoform is more efficient at
hydrolyzing paraoxon than a Q isoform (Smolen et al., 1991; Humbert et al., 1993;
Richter and Furlong, 1999). Additional studies have shown the reverse of the isoform
efficiency for diazoxon and the nerve agents soman and sarin (Davies et al., 1996). All
isozymes have activity toward chlorpyrifos-oxon and the standard arylesterase substrate,
phenyl acetate (Furlong et al., 1993; Davies et al., 1996). A substitution of a leucine or a
methionine at residue 55 has been shown to result in differences in both enzyme activity
and concentration (PON1 protein) (Adkins et al., 1993; Mackness et al., 1997). These
studies and others demonstrate the role both genotype and concentration of PON1 play in
an individual’s ability to detoxify OPs (La Du and Eckerson, 1986; Geldmacher-von
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Mallinkrodt and Diepgen, 1988; Furlong et al., 1993; Davies et al., 1996; Clendenning et
al., 1996; Richter and Furlong, 1999; Akgur et al., 1999).
Associations of PON1 polymorphisms and disease states such as cardiovascular
disease, type 2 diabetes, Parkinson’s disease, and Alzheimer’s disease have been
increasingly studied over the last several years (Herrmann et al., 1996; Sanghera et al.,
1997; Laplaud et al., 1998; Cascorbi et al., 1999; Aynacioglu and Kepekci, 2000;
Gardemann et al., 2000; Kondo and Yamamoto, 1998; Akhmedova et al., 1999; Kalman
et al., 1999; Sodeyama et al., 1999, Jarvik et al., 2000, Davis et al., 2009; Coombes et
al., 2014; Crow et al., 2018). Studies have indicated that PON1 activities can be
increased with exercise and diets rich in nuts and pomegranate juice (Costa et al., 2005).
Other studies have shown that cigarette smoking and some medications (e.g., statins)
appear to have an inhibitory effect on PON1 activity (Nishio and Watanabe, 1997; James
et al., 2000; Mackness et al., 2012).
PON1 has been shown to hydrolyze many substrates, including phenyl acetate
(arylesterase activity) and some organophosphates (Furlong et al., 1993). More recently,
researchers have discovered PON1’s ability to hydrolyze some lactones (Mackness et al.,
1991; Billecke et al., 2000; Biggadike et al., 2000; Jakubowski, 2000). It is now
speculated that PON1’s endogenous function is as a lipolactonase (Jakubowski, 2000).
PON1 has been shown to inactivate toxic products that result from the oxidation of lipid
components of low-density lipoproteins (LDL). This action may play a role in preventing
the development of atherosclerosis and ultimately cardiovascular disease (Mackness et
al., 1993; Aviram et al., 1998).
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PON2 is an intracellularly expressed enzyme found in the brain, liver, lung,
kidney, heart, pancreas, small intestine, muscle, testis, endothelial cells, tracheal
epithelial cells, and macrophages, but unlike PON1 and PON3, it is not present in serum
(Ng et al., 2001). PON2 has very little hydrolytic activity towards OPs. PON2 functions
primarily as a lactonase and may play a role in determining susceptibility to oxidative
stress and neuroinflammation (Draganov et al., 2005; Levy et al., 2007)
PON3, similar to PON1, is synthesized in the liver and is associated with HDL in
the serum. (Draganov et al., 2000). Like PON2, PON3 does not hydrolyze OPs but has
been shown to hydrolyze lactones, such as statins. PON3 been shown to have both
antioxidant and anti-inflammatory potential. Though the antioxidant mechanisms of
PON3 in disease states are not well characterized, it may play a role in a variety of
oxidative-stress related diseases such as atherosclerosis, metabolic syndrome, HIV, and
chronic liver disease (Reddy et al., 2001; Draganov et al., 2005).
Carboxylesterase
Carboxylesterases (CaE; EC 3.1.1.1) are serine esterases (Aldridge, 1953) that can
hydrolyze several different types of endogenous and exogenous compounds (Satoh and
Hosokawa, 2006; Zou et al., 2018). CaEs are products of a multigene family that exist in
several isozyme forms (Satoh and Hosokawa, 2006; Ross et al., 2012). CaEs hydrolyze
aliphatic and aromatic esters and amides, and can activate some carcinogens (Satoh,
1987; Hosokawa et al., 1987; Maki et al., 1991; Zou et al., 2018). Substrates of
carboxylesterases include steroids (Lund-Pero et al., 1994), salicylates (White et al.,
1994), cocaine (Dean et al., 1995; Brzezinski et al., 1994), heroin (Brzezinski et al.,
23

1997; Pindel et al., 1997) as well as some organophosphates (Maxwell et al., 1988; Pond
et al., 1990; Fukuto, 1990; Chambers and Carr, 1993; Satoh and Hosokawa, 2006; Zou et
al., 2018).
Carboxylesterases, also termed aliesterases, are important in detoxication of
organophosphate insecticides (Chambers, 1990; Fukuto, 1990; Satoh and Hosokawa;
2006). Like acetylcholinesterase, CaEs are members of the B-esterase family (Aldridge,
1953). CaEs can be stoichiometrically inhibited by many OP oxons, thus detoxifying
OPs by removing them from circulation prior to reaching the target AChE (Pond et al.,
1990; Moser et al., 1998). The inhibition of CaE by OPs does not directly affect survival
but provides a non-catalytic detoxication pathway, in essence providing a “sink” to draw
down circulating OP oxons. The degree of OP detoxication by CaEs depends both on the
affinity for the OP and the concentration of the enzyme (Fukuto, 1990; Chambers et al.,
1994; Ross et al., 2012). Some of the OPs that are good inhibitors for CaE include
paraoxon, chlorpyrifos-oxon, and malaoxon. (Maxwell et al., 1988; Clement, 1984;
Fonnum et al., 1985; Gupta et al., 1985; Gupta and Dettbarn, 1987; Jokanovic, 1989;
Chambers et al., 1990; Gaustad et al., 1991; Maxwell, 1992; Chambers and Carr, 1993;
Moser et al., 1998; Moser and Padilla, 2016). CaE can also hydrolyze parent OP
insecticides containing carboxylic esters in their structure (e.g., malathion). This
hydrolysis is catalytic and is an efficient detoxication pathway in mammals that results in
low mammalian toxicity for malathion (Main and Braid, 1962; Talcott, 1979; Fukuto,
1990; Satoh and Hosokawa, 1998; Buratti and Testai, 2005).
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CaEs are glycoproteins and are ubiquitous in a variety of tissues, including liver,
kidney, intestine, skin, heart, muscle, lung, adipose, and blood with the liver containing
the greatest activity, especially in the microsomal fraction (McCracken et al., 1993;
Morgan et al., 1994; Zou et al., 2018). CaE isozymes have been divided into several
families in mammals labeled CES followed by a number to reflect the isozyme family
(Zou et al., 2018), with the CES1 family including the major CaE forms responsible for
OP detoxication in both rats and humans (Yan et al., 1995; Crow et al., 2008; Ross et al.,
2012; Zou et al., 2018). The CES1A1 family contains the major human isoforms, while
CES1A2 contains the major isoforms of rat, mouse, dog, and rabbit carboxylesterase
(Satoh and Hosokawa, 1998). CaEs have several conserved motifs with a catalytic triad
of residues at the active center of the enzyme (serine 203, glutamate 335, and histidine
448) that are particularly conserved (Cygler et al., 1993).
CaEs have been shown to be induced by several different chemicals in rodents.
Inducers of CaE include phenobarbital (Hosokawa et al., 1984), polycyclic aromatic
hydrocarbons (Hosokawa et al., 1988), synthetic glucocorticoids, and clofibrate
(Mentlein et al., 1986), many of which also induce CYP. Chemical inhibitors of CaE
include tri-o-tolyl phosphate (TOTP), bis-(4-nitrophenyl)phosphonate (BNPP),
tetraisopropyl pyrophosphoramide (iso-OMPA), or 2-(o-cresyl)-4H-1,3,2benzodioxaphosphorin-2-oxide (CBDP) and saligenen cyclic phenylphosphonate (SCPP)
(Casida, 2016; Zou et al., 2018). These inhibitors can be used experimentally to
selectively inhibit the amount of functional CaE to determine the role of CaEs in
detoxication pathways of other chemicals that are CaE substrates (Zou et al., 2018).
25

CaE has been shown to increase with age from birth to weaning in rodents,
resulting in greater susceptibility to OP toxicity in younger animals (Clement, 1984; Peet
et al., 1987; Chambers et al., 1990; Atterberry et al., 1997; Moser et al., 1998; Karanth
and Pope, 2000; Padilla et al., 2000). Clement (1984) demonstrated that a developmental
increase in CaE in rat liver and plasma correlated well with a decrease in the toxicity of
the nerve agent soman. In another study in rats, an increase in liver CaE activity with age
correlated with a decrease in the sensitivity to the insecticides parathion and chlorpyrifos
(Burnett and Chambers, 1994). CaE expression in livers from humans has been shown to
be low in children less than 3 weeks of age followed by a rapid increase by 6 years of age
(Hinds et al., 2016). Sex differences in CaE activity have also been reported in rats.
Moser et al. (1998) reported that adult female rats had lower CaE activities than adult
males. Unlike rats, humans do not have CaE in their serum (Zou et al., 2018) which can
be a confounder when extrapolating OP toxicity from rats to humans. The abundance of
CaE in mammalian tissues and its ability to hydrolyze many OPs make it a very
important in assessing the toxicity of OPs.
Research Summary
This research study was designed to determine the age-related differences for
activation (cytochrome P450 mediated), detoxication and toxicity (target enzyme
sensitivity) for several OP compounds that display a variety of chemistries and a common
mechanism of toxicity. The overall hypothesis of this study is the lower vulnerability of
adults to the toxic effects of some organophosphates is primarily the result of the
maturation of enzymes capable of organophosphate detoxication and less likely the result
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of differences in activation to their active metabolites (oxons) and/or the sensitivity of the
target enzyme acetylcholinesterase.
The objectives of this research were to 1) determine the differences in AChE,
BChE, and CaE sensitivity in several tissues to a series of OP oxons with a variety of
leaving groups in three ages of rats; 2) investigate the differences in rates of CYP
mediated activation (desulfuration) of the OP, malathion, in human (various ages) and rat
liver microsomes and determine the major detoxication pathways of malathion and the
active metabolite, malaoxon, using the same microsomes; and 3) investigate the
differences in inhibitory rates for AChE by malaoxon in both human (various ages) and
rat (adult) erythrocyte ghosts.
The OPs chosen for the initial portion of this study (chapter II) include the
anticholinesterase metabolites (oxons) of some commercially available insecticides and
some model compounds. The age-related sensitivity of the target enzyme, AChE, as well
as two of the non-target (detoxication) enzymes, CaE and BChE, were determined in
vitro by determining IC50s for each of 12 OPs in a variety of tissues from rats of three
ages (post-natal day 1, PND1; PND12; and PND70). IC50s provide a good estimate of an
inhibitor’s potency; however, it does not describe the various steps in the enzymatic
reaction. With the large number of compounds and the limited amount of tissue available
from the young rats, IC50s were chosen for this portion of the project to compare the
potency of a given OP (12) among the 3 age groups. The inhibitory potency of OPs for
the target enzyme AChE as well as the potency of OPs for the stoichiometric detoxication
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enzymes, BChE and CaE, can provide information to help explain the differences in the
toxicity of OPs with different structural characteristics.
The differences in OP toxicities in relation to structure has been investigated for
many years in our laboratory and others. The widely used OP, malathion, has a very low
mammalian toxicity (LD50 > 1 g/kg in rats); however, the active metabolite, malaoxon, is
a reasonably good inhibitor of AChE in vitro. Differences in the activation and/or
detoxication could provide an explanation for this discrepancy in the in vitro potency and
the in vivo toxicity. The activation and detoxication potential for malathion were
investigated using rat and human liver microsomes in chapter III.
The metabolism of malathion is complex and the pathways are difficult to
separate kinetically due to several of the processes occurring essentially simultaneously
including 1) the activation of malathion to malaoxon by CYP 2) the catalytic degradation
of malathion by carboxylesterase and 3) the stoichiometric detoxication of malaoxon by
carboxylesterase. Kinetic constants (Vmax and Km) for the CYP mediated activation of
malathion to its anticholinesterase metabolite, malaoxon, were determined in rat and
human (various ages) liver microsomes. In addition, the detoxication potential of the
same microsomes for malathion and malaoxon was investigated. Carboxylesterase was
determined to be important in the degradation of both malathion and malaoxon.
Paraoxonase was determined to not be an important enzyme in the detoxication of
malaoxon.
The determination of kinetic constants of activation for malathion and as well as
identifying the enzymatic pathways involved in degradation of malathion and malaoxon
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will be useful in the development of physiologically based pharmacokinetic (PBPK)
models. These predictive models utilize a series of differential equations to
mathematically describe the physiologic, biochemical, and physicochemical reactions
that contribute to the pharmacokinetics of a compound. A well constructed and validated
PBPK model can provide very accurate predictions for acute or chronic exposures for a
given compound (Clewell and Anderson, 1985). PBPK models use engineering
principles that are applied to biological systems. These models use mathematical
descriptors for various compartments (organ systems) and the processes within these
compartments. Each compartment can consist of diffusion rates, enzyme systems, and
rates of those enzyme mediated processes. Physicochemical properties of the compound
of interest must also be considered including structure, molecular weight, volatility,
stability, and lipophilicity. For a PBPK model to accurately predict a response for a
given exposure, it requires experimentally derived parameters including rates for a
compound’s absorption, distribution, metabolism, detoxication and elimination.
A PBPK model can estimate a tissue dose and subsequent response (forward
dosimetry) for an administered dose of a compound. In addition, some PBPK models can
use biomonitoring data (measured tissue dose) to estimate an exposure level (reverse
dosimetry). PBPK models for toxic compounds in humans usually require data derived
in animal models that are extrapolated to humans (interspecies) for a given dose and route
of exposure. The interspecies variability in activation rates (human and rat microsomes)
for malathion as well as the intraspecies (27 microsomes from humans of different ages)
variability in activation rates were determined and may be valuable in developing a
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human PBPK model for malathion. These kinetic parameters and models will be useful
in determining the levels of safety factors to be applied in the risk assessment of
malathion.
The kinetic rates for malathion activation (desulfuration) in rat and human
microsomes were calculated according to concepts developed by Leonor Michaelis and
Maud Menten. In 1913, Michaelis and Menten demonstrated that the rate of an enzymecatalyzed reaction is proportional to the enzyme-substrate complex. The equation
follows a mechanism in which substrate binds reversibly to an enzyme to form an
enzyme-substrate complex, which then reacts irreversibly and generates a product and the
free enzyme (Michaelis and Menten, 1913; Goody and Johnson, 2011). This widely used
equation was used to calculate the maximum velocity (Vmax) and substrate affinity (Km)
for the activation (desulfuration) of malathion to its anticholinesterase metabolite,
malaoxon. These rates were obtained to determine differences in rat and human
microsomes and differences with respect to age in human microsomes.
The kinetics of AChE inhibition by the active metabolite of malathion, malaoxon,
were determined using human and rat erythrocyte ghosts (chapter IV). The difference in
rates of AChE inhibition (bimolecular rate constants) will be valuable in the construction
of PBPK models for human exposure to malathion based on both rat and human
experimental data. The development and validation of these models is dependent on
bimolecular rate constants calculated from measured AChE inhibition for increasing
concentrations of inhibitor over a given time. The differences between rat and human
bimolecular rate constants will be valuable in assessing interspecies safety factors in the
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risk assessment for malathion. Double-reciprocal plots, commonly referred to as
Lineweaver-Burk plots, were used to plot the best fit line for velocity versus the inhibitor
concentration (1/ln (% AChE activity (kapp) versus 1/inhibitor concentration) (Lineweaver
and Burk, 1934). A major concern with the Lineweaver-Burk model is the heavier
weight of the lower concentrations and its effect on the slope of the line (Dowd et al.,
1965); therefore, thanks to newer computer software, the rates of inhibition (Vo) were
plotted versus substrate concentration producing a hyperbolic curve and using non-linear
regression more accurate rate constants can be calculated. Bimolecular rate constants (ki)
constants were calculated for malaoxon from both the double-reciprocal plots and
hyperbolic plots. The knowledge of reaction rates is important for comparative analysis
between different OP compounds and their interaction with the target enzyme as well as
interspecies and intraspecies comparisons (Kitz and Wilson, 1962; Carr and Chambers,
1993; Worek et al., 2002; Coban et al., 2016). Our lab and others have previously
reported inhibition rate constants for several OP insecticides, model OP compounds and
nerve agents. This research focused on determining AChE inhibition rate constants for
malaoxon in human and rat erythrocyte membranes to determine interspecies and
intraspecies differences. These rate constants can be used in the development of a PBPK
model for malathion and ultimately in the overall risk assessment for this heavily used
insecticide.
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CHAPTER II
IN VITRO AGE-RELATED DIFFERENCES IN RATS TO ORGANOPHOSPHATES
Introduction
Organophosphate (OP) insecticides are widely used for a variety of agricultural
applications throughout the United States and all over the world. Their major mechanism
of toxic action is the inhibition of the serine hydrolase acetylcholinesterase (AChE) in
synapses and neuromuscular junctions resulting in an accumulation of the
neurotransmitter acetylcholine and ultimately hyperstimulation of the nervous system
(Hayes and Laws, 1991; Ecobichon, 1996). The majority of OP insecticides undergo
bioactivation via cytochrome P450 (CYP) to oxon metabolites, which are active
anticholinesterases (Kulkarni and Hodgson, 1980; Sultatos et al., 1985; Chambers and
Chambers, 1989; Fukuto, 1990).
Non-target esterases, such as carboxylesterases (CaEs) and butyrylcholinesterases
(BChEs), can stoichiometrically bind oxon metabolites of OPs and limit the amount of
OP available to target AChE, thus providing some protection to the organism (Aldridge,
1953; Russell and Overstreet, 1987; Chambers et al., 1990; Fukuto, 1990; Maxwell,
1992; Chambers and Carr, 1993; Chambers et al., 1994; Pond et al., 1995; Mileson et al.,
1998; Moser and Padilla, 2016). Studies have shown that CaE activity in rats increases
with age from birth to young adulthood, suggesting that neonates and juveniles would not
have the same level of protection (detoxication) from an OP exposure as adult animals
56

(Clement, 1984; Maxwell, 1992; Atterberry et al., 1997; Tang et al., 1999). Hinds et al.
(2016) showed an increase in hepatic CaE activity with age in human pediatric patients
indicating a potential for greater OP toxicity in children.
In addition to CaEs and BChEs, some OPs can be hydrolyzed effectively by Aesterases (Aldridge, 1953; Furlong et al., 1989; Chambers et al., 1994; Pond et al., 1995).
A-esterase, also termed paraoxonase (PON), is a calcium dependent enzyme synthesized
in the liver and is associated with high density lipoproteins (HDLs) in the serum
(Mackness et al., 1985; Furlong et al., 1989; Pond et al., 1995). Paraoxonase is a
multigene family, including PON1, PON2, and PON3 (Primo-Parmo et al., 1996), with
PON1 capable of catalytically hydrolyzing some OP compounds thus providing
protection for the target enzyme AChE (Costa et al., 1990; Chambers et al., 1994; Le et
al., 1995; Pond et al., 1995; Mortensen et al., 1996). Similar to CaE, PON1 has been
shown to increase with age in rats from birth to young adulthood (Atterberry et al., 1997;
Moser et al., 1998).
OP insecticides display a wide range of acute toxicities mostly due to the variety
of their chemistries. Generally, the insecticidal OPs are either O,O-dimethyl or O,Odiethyl phosphates, phosphorothionates, and phosphorothionothiolates (Fukuto, 1990;
Hayes and Laws, 1991; Chambers et al., 1992). The differences in the chemistries of the
insecticides result in differences in the compounds' metabolism (activation and
detoxication) (Aizawa, 1982; Chambers et al., 1990; Chambers et al., 1994; Atterberry et
al., 1997; Mileson et al., 1998). Studies from our laboratory and others have
demonstrated that the metabolic bioactivation of OPs to their active oxon metabolites can
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increase their potency as AChE inhibitors by several orders of magnitude (Chambers and
Chambers, 1989; Forsyth and Chambers, 1989; Fukuto, 1990; Mileson et al., 1998).
In adult mammals, the acute toxicity levels of individual OP insecticides appear to
be principally dependent on the compound-specific efficiencies of detoxication, and less
dependent upon the differences in CYP activation and/or sensitivity of the target enzyme,
AChE (Chambers et al., 1990; Chambers et al., 1994; Atterberry et al., 1997; Pope et al.,
2005). Previous studies suggested little age-related differences in in vitro rat brain AChE
sensitivity to chlorpyrifos-oxon and malaoxon (Mortensen et al., 1996, 1998) or paraoxon
and methyl paraoxon (Benke and Murphy, 1975, Atterberry et al.,1997). In addition,
several studies have shown that adult animals are less susceptible to acute exposures of
OP insecticides than younger animals (Brodeur and Dubois, 1963; Gagne and Brodeur,
1972; Benke and Murphy, 1975, Pope et al., 1991; Atterberry et al., 1997). Mortensen et
al. (1998) also compared the sensitivity of purified AChE from brain and plasma of
neonate and adult rats to chlorpyrifos-oxon and found no age-related differences.
Although age-related differences in CYP-mediated bioactivation (desulfuration) and
detoxication (dearylation) of OPs has been documented (Atterberry et al., 1997), the
maturation of OP detoxication enzymes appears to be the primary factor in the toxicity
level for most OPs in young animals.
The current in vitro investigation was designed to determine the age-related
sensitivity of acetylcholinesterase and carboxylesterase to 12 OP compounds that display
a variety of chemistries. The OPs chosen for this study include 8 diethyl and 4 dimethyl
oxons (the anticholinesterase metabolite of the OP) of which some are the active
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metabolites of commercially available insecticides and some are model compounds. This
work will support other studies that have investigated the age-related differences in acute
toxicity of a select number of commercially available organophosphates and provide
additional information about the structure/anticholinesterase activity relationship for OPs
as well as the sensitivity of OP detoxication enzymes.
Materials and Methods
Chemicals
All organophosphates/oxons (Table 1) were synthesized by Dr. Howard
Chambers at Mississippi State University using standard procedures from commercially
available intermediates (Chambers and Chambers, 1989; Meek et al., 2011), except
diazoxon which was purchased from ChemService (West Chester, PA) and azinphosmethyl-oxon which was a generous gift of Bayer Crop Protection (Stilwell, KS). All
organophosphates were at least 95% pure. All other reagent grade chemicals were
purchased from Sigma Chemical Co. (St. Louis, MO). Figure 1 displays the chemical
structures for the 12 OP compounds tested in this study.
Organophosphates
The 12 OPs tested in this study were selected for their differences in structure
(Figure 1) which were predicted to demonstrate unique inhibitory and detoxication
potential. By selecting the active metabolites “oxons” for testing, this strategy eliminates
the involvement of CYP-mediated bioactivation (desulfuration) and detoxication
(dearylation) and allows for the determination of the sensitivity of the target enzyme,
AChE, as well as the non-target protective esterases. Data from our laboratory and others
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suggests that esterase mediated hydrolyses are more important in the overall toxicity level
of OPs than the differential efficiencies of CYP-mediated bioactivation and detoxication.
Of the 12 compounds selected for study, four (chlorpyrifos-oxon, paraoxon, methylparaoxon and diazoxon) have an extensive literature database for comparing data
generated in this investigation. The additional eight compounds are either commercial
insecticides, metabolites (oxons) of commercial insecticides, or model OPs with unique
chemistries. These compounds were selected for their biochemical characteristics that
were predicted to result in a wide range of potencies.
Animals
Rats were the source of tissues for the in vitro testing of OP oxon potencies. Male
Sprague Dawley-derived (Crl:CD(SD)BR) rats at postnatal days (PND) 1, 12, and 70
were obtained from breeding colonies derived from rats purchased from Charles River
Laboratories and maintained at Mississippi State University (PND 1 and 12) or were
purchased (PND 70) from Charles River Laboratories. Rats were housed in AAALAC
accredited facilities within the College of Veterinary Medicine at Mississippi State
University with temperature-controlled environments and 12 h dark-light cycle. Standard
lab chow and tap water were provided ad libitum. All animal procedures received prior
approval from the Mississippi State University Animal Care and Use Committee. Sex
differences were not expected to be appreciable in neonates and juveniles; therefore, to
reduce animal numbers and confounders such as time of estrus cycle in adult females,
rats of only one sex (male) were chosen for study. The ages of rats were selected to
represent a range of developmental stages and enzymatic activities, which have been
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shown to mature with age in our laboratories and many others. PND 1 was chosen as a
neonatal age in rats, with rats of this age reported to have low levels of protective
(detoxication) esterases. PND 12 was selected because studies have reported significant
increases in protective esterases at this age in rats (Gagne and Brodeur, 1972). PND 70
was selected as young adults with a full complement of protective esterases (Atterberry et
al., 1997). The choice of ages was not intended to equate to any particular age in
humans.
Tissue Collection and Preparation
Brain, heart, skeletal muscle, lung, liver and blood were collected from naïve
PND 1, 12, and 70 male Sprague Dawley rats. The tissues were rinsed in ice cold 0.9%
saline, immediately snap-frozen in liquid nitrogen and stored at -80ºC. The serum was
prepared by centrifuging the blood at 10,000 g for 8 min, separated from sedimented
erythrocytes, and was stored at -80ºC. Three different pools of each rat tissue (brain,
heart, skeletal muscle, and lung) were utilized for experimental replication. Each pool
consisted of six individual rat tissues and represented a single replication. Solid tissues
were minced with scissors on ice and homogenized in 0.05 M Tris-HCl buffer (pH 7.4 at
37oC) with a motorized homogenizer (Wheaton or Polytron). Serum was diluted with
0.05 M Tris-HCl buffer (pH 7.4 at 37oC). Immediately prior to testing, tissues were
diluted to the following final concentrations (FC; mg tissue/ml 0.05 M Tris-HCl buffer
(pH 7.4 at 37oC)): brain, 1 mg/ml; heart, 5 mg/ml; skeletal muscle, 5 mg/ml; lung, 2.5
mg/ml; serum, 10 µl/ml for cholinesterase assays and 0.5 mg/ml and 5 µl/ml for lung and
serum carboxylesterase, respectively.
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Esterase Activities
Enzymatic activity was determined for each tissue from PND 1, PND 12, and
PND 70 rats. Acetylcholinesterase activity was determined for brain, heart, lung, skeletal
muscle and serum using a discontinuous spectrophotometric assay (modification of
Ellman et al., 1961) with acetylthiocholine as the substrate and 5,5'-dithiobis(nitrobenzoic acid) (DTNB) as the chromogen (Chambers et al., 1988). Briefly, tissue
homogenates were diluted (2 ml total assay volume) in buffer (0.05M Tris-HCl buffer
(pH 7.4 at 37oC)), vortexed, and placed in a shaking water bath preheated to 37ºC.
Additional tubes (blanks) containing eserine sulfate (FC, 10 µM) were included in the
assay to inhibit AChE and correct for non-enzymatic hydrolysis. Each assay contained
triplicate subsamples for each tissue as well as duplicate eserine sulfate blanks.
Following the initial incubation, 20 µl of acetylthiocholine (FC, 1 mM) was added as a
substrate for AChE and was incubated for an additional 15 min. The reaction was
terminated and color was developed using 250 μl of a 5% SDS/0.24 M DTNB mixture
(4:1). Absorbance was measured at 412 nm using a spectrophotometer. Serum
butyrylcholinesterase activity was determined by the same method as serum
acetylcholinesterase activity with the substitution of butyrylthiocholine (FC, 1mM) for
acetylthiocholine as the substrate. Liver and serum carboxylesterase activities were
determined according to the method of Chambers et al. (1990) using p-nitrophenyl
valerate (pNPV) as the substrate for CaE. Dilute homogenates of liver or serum (total
assay volume: 2 ml for liver, 1 ml for serum), were vortexed and placed in a shaking
water bath preheated to 37ºC. Tubes (blanks) containing paraoxon (FC, 10 µM) were
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included in the assay to inhibit CaE and correct for non-enzymatic hydrolysis. Each
assay contained triplicate subsamples for each tissue as well as duplicate paraoxon
blanks. Following an initial incubation of 15 min, 20 µl of pNPV (FC, 500 µM) in
ethanol vehicle was added as a substrate for the remaining uninhibited CaE and was
incubated for an additional 15 min. The reaction was terminated with 500 μl of a 2%
SDS/2% Tris-base mixture. Absorbance was measured at 405 nm using a
spectrophotometer. The assays were run three times using a unique set of reagents for
each assay. Protein content for each tissue was quantified by the method of Lowry et al.
(1951) using bovine serum albumin as the standard. Specific activities were calculated as
nmoles min-1mgP-1.
In Vitro Acetylcholinesterase IC50 Determination
The inhibitory concentration 50 (IC50) of a compound represents the concentration
at which 50% of a given enzyme’s activity is inhibited. IC50s are often determined as an
index of potency for a chemical inhibitor. For this study, AChE IC50s were determined
for each of 12 organophosphates in each of four rat tissues using a discontinuous
spectrophotometric assay (modification of Ellman et al., 1961) with acetylthiocholine as
the substrate and 5,5'-dithio-bis(nitrobenzoic acid) (DTNB) as the chromogen (Chambers
et al., 1988). Briefly, tissue homogenates were diluted (2 ml total assay volume) in
buffer (0.05M Tris-HCl buffer (pH 7.4 at 37oC)) and 20 µl of ethanol vehicle or one of
five concentrations of each OP oxon in ethanol vehicle were added, vortexed, and placed
in a shaking water bath preheated to 37ºC. Additional tubes (blanks) containing eserine
sulfate (FC, 10 µM) were included in the assay to inhibit AChE and correct for non63

enzymatic hydrolysis. Each assay contained triplicate subsamples for vehicle controls
and each inhibitor concentration as well as duplicate eserine sulfate blanks. Following
the initial incubation, 20 µl of acetylthiocholine (FC, 1 mM) was added as a substrate for
the remaining uninhibited AChE and was incubated for an additional 15 min. The
reaction was terminated and color was developed using 250 μl of a 5% SDS/0.24 M
DTNB mixture (4:1). Absorbance was measured at 412 nm using a spectrophotometer.
Percent inhibition of control (EtOH vehicle) absorbance was calculated for each
concentration. IC50 values were determined by linear regression analysis of the plot of
the logit of percent inhibition versus log10 oxon concentration. The best-fit line was
drawn using points corresponding to the 20-80 percent AChE inhibition range and the
equation of the best-fit line was solved for the x-intercept to determine the IC50. The
procedure was used for brain, heart, lung, and skeletal muscle. The assays were run three
times using a unique set of reagents for each assay.
In Vitro Serum AChE and BChE IC50 Determination
The determination of serum AChE and BChE IC50s requires the usage of specific
inhibitors to separate AChE and BChE activities. For the determination of both serum
AChE and BChE IC50s, 10 µl of serum was added to 990 µl of 0.05M Tris-HCl buffer
(pH 7.4 at 37oC) for a total assay volume of 1 ml. Ten microliters of 0.1 M EDTA was
added to the dilute serum to inhibit A-esterase (paraoxonase) preventing any catalytic
hydrolysis of oxons by paraoxonase. Ethopropazine (FC, 1 μM), a selective BChE
inhibitor, was added to inhibit all BChE activity leaving AChE functional. In parallel
samples, a selective AChE inhibitor (BW284C51) was added to inhibit all AChE activity
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leaving BChE functional. Ten microliters of ethanol vehicle or one of five concentrations
of each OP in ethanol vehicle were added, vortexed, and placed in a shaking water bath
preheated to 37ºC. Additional tubes (blanks) containing eserine sulfate (FC, 10 μM)
were included in the AChE assay to inhibit AChE and correct for non-enzymatic
hydrolysis. Blank tubes for the BChE assay contained iso-OMPA (tetraisopropyl
pyrophosphoramide, FC, 10 μM) to inhibit BChE and correct for non-enzymatic
hydrolysis. Each assay contained triplicate subsamples for vehicle controls and each
inhibitor concentration as well as duplicate blanks. Following an initial incubation of 15
min, 10 µl of acetylthiocholine (FC, 1 mM) or butyrylthiocholine (FC, 1 mM) was added
as a substrate for the remaining uninhibited AChE or BChE, respectively, and was
incubated for an additional 15 min. The reaction was terminated and color was
developed using 125 μl of a 5% SDS/0.24 M DTNB mixture (4:1). Absorbance was
measured at 412 nm using a spectrophotometer. Percent inhibition of control (EtOH
vehicle) absorbance was calculated for each concentration. IC50 values were determined
by linear regression analysis of the plot of the logit of percent inhibition versus log10
oxon concentration. The best-fit line was drawn using points corresponding to the 20-80
percent AChE or BChE inhibition range and the equation of the best-fit line was solved
for the x-intercept to determine the IC50. The assays were run three times using a unique
set of reagents for each assay.
In Vitro Liver Carboxylesterase IC50 Determination
Liver tissue was homogenized in 0.05M Tris-HCl buffer (pH 7.4 at 37oC). The
liver homogenate was assayed according to the method of Chambers et al. (1990) using
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p-nitrophenyl valerate (pNPV) as the substrate for CaE. To determine CaE IC50s for each
of the 12 OPs, 20 µl of ethanol vehicle or one of five concentrations of each OP in
ethanol vehicle was added to dilute homogenates (2 ml total assay volume), vortexed, and
placed in a shaking water bath preheated to 37ºC. Tubes (blanks) containing paraoxon
(FC, 10 µM) were included in the assay to inhibit CaE and correct for non-enzymatic
hydrolysis. Each assay contained triplicate subsamples for vehicle controls and each
inhibitor concentration as well as duplicate paraoxon blanks. Following an initial
incubation of 15 min, 20 µl of pNPV (FC, 500 µM) in ethanol vehicle was added as a
substrate for the remaining uninhibited CaE and was incubated for an additional 15 min.
The reaction was terminated with 500 μl of a 2% SDS/2% Tris-base mixture.
Absorbance was measured at 405 nm using a spectrophotometer. Percent inhibition of
control (EtOH vehicle) absorbance was calculated for each concentration. IC50 values
were determined by linear regression analysis of the plot of the logit of percent inhibition
versus log10 OP concentration. The best-fit line was drawn using points corresponding to
the 20-80 percent CaE inhibition range and the equation of the best-fit line was solved for
the x-intercept to determine the IC50. The assays were run three times using a unique set
of reagents for each assay.
In Vitro Serum Carboxylesterase IC50 Determination
Serum was diluted at a concentration of 5 µl/ml in 0.05M Tris-HCl buffer (pH 7.4
at 37oC). The dilute serum (1 ml total assay volume) was assayed according to the
method of Chambers et al. (1990) using p-nitrophenyl valerate (pNPV) as the substrate
for CaE. To determine CaE IC50s for each of the 12 OPs in this study, 10 µl of ethanol
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vehicle or one of five concentrations of each OP in ethanol vehicle were added, vortexed,
and placed in a shaking water bath preheated to 37ºC. Tubes (blanks) containing
paraoxon (FC, 10 μM) were included in the assay to inhibit CaE and correct for nonenzymatic hydrolysis. Each assay contained triplicate subsamples for vehicle controls
and each inhibitor concentration as well as duplicate paraoxon blanks. Following an
initial incubation of 15 min, 10 µl of pNPV (FC, 500 µM) in ethanol vehicle was added
as a substrate for the remaining uninhibited CaE and was incubated for an additional 15
min. The reaction was terminated with 250 μl of a 2% SDS/2% Tris-base mixture.
Absorbance was measured at 405 nm using a spectrophotometer. Percent inhibition of
control (EtOH vehicle) absorbance was calculated for each concentration. IC50 values
were determined by linear regression analysis of the plot of the logit of percent inhibition
versus log10 OP concentration. The best-fit line was drawn using points corresponding to
the 20-80 percent CaE inhibition range and the equation of the best-fit line was solved for
the x-intercept to determine the IC50. The assays were run three times using a unique set
of reagents for each assay.
In Vitro Serum AChE IC50 Determination Using Specific Inhibitors
Subsequently, additional experiments were conducted with adult serum to
selectively inhibit non-target (detoxication) esterases (paraoxonase, carboxylesterase and
butyrylcholinesterase). For these experiments, 10 µl of EDTA (1 mM), 10 µl of saligenin
cyclic phenylphosphonate, SCPP, (FC, 50 nM) and 10 µl ethopropazine (FC, 1 μM) were
added to adult rat diluted serum to inhibit paraoxonase, carboxylesterase, and
butyrylcholinesterase, respectively, leaving AChE functional. Ten microliters of ethanol
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vehicle or one of five concentrations of each OP in ethanol vehicle were added, vortexed,
and placed in a shaking water bath preheated to 37ºC. Additional tubes (blanks)
containing eserine sulfate (FC, 10 µM) were included in the assay to inhibit AChE and
correct for non-enzymatic hydrolysis. Each assay contained triplicate subsamples for
vehicle controls and each inhibitor concentration as well as duplicate eserine sulfate
blanks. Following the initial incubation, 10 µl of acetylthiocholine (FC, 1 mM) was
added as a substrate for the remaining uninhibited AChE and was incubated for an
additional 15 min. The reaction was terminated and color was developed using 125 μl of
a 5% SDS/0.24 M DTNB mixture (4:1). Absorbance was measured at 412 nm using a
spectrophotometer. Percent inhibition of control (EtOH vehicle) absorbance was
calculated for each concentration. IC50 values were determined by linear regression
analysis of the plot of the logit of percent inhibition versus log10 OP concentration. The
best-fit line was drawn using points corresponding to the 20-80 percent AChE inhibition
range and the equation of the best-fit line was solved for the x-intercept to determine the
IC50. The assays were run three times using a unique set of reagents for each assay.
Statistics
Specific activities for each tissue were analyzed by an analysis of variance
(ANOVA) using SAS software on a personal computer with mean separation by the
Student-Newman-Keuls (SNK) post-hoc test. Significant difference among ages is
reported for the p < 0.05 level. IC50s were calculated as the mean of three independent
linear regressions using Excel software and mean IC50s were subsequently analyzed
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using SAS software on a PC with significant difference among ages determined by a lack
of overlap of 95% Confidence Intervals for each compound.
Results
Acetylcholinesterase activities of brain significantly increased with age. Activity
was 1.8-fold higher in juveniles than neonates and 2.2-fold higher in adults than neonates.
The AChE activities of the peripheral tissues (heart, lung, and skeletal muscle) increased
with age with PND 70 animals having significantly higher activities than PND 12s and
PND 1s. Although activities were trending higher for PND 12s compared to PND 1s no
significant differences were determined. Serum AChE activity was not significantly
different among the three ages; however, serum BChE activities were significantly higher
in PND 70 animals compared to PND 12 and PND 1 animals. Carboxylesterase activities
for both liver and serum were significantly different among all three ages. The hepatic
CaE activities of the PND 70 rats were about 2-fold higher than the PND 12 rats and
about 8-fold higher than the PND 1 rats. Hepatic CaE activities increased 3.8-fold from
PND 1 to PND 12. A similar increase was determined within serum among all three ages
(Table 2). Adult rat tissues all had significantly higher protein levels than neonate or
juvenile tissues (Table 3).
IC50s were determined using equivalent amounts of tissue within a tissue for all
three ages; therefore, the activities were different for some age groups. The diethyl
insecticidal OPs were generally more potent AChE inhibitors than the dimethyl OPs as
indicated by the IC50s for brain, heart, lung, skeletal muscle and serum (Table 4-5). The
two model diethyl OPs, ethyl ronnel-oxon and ethyl cyanophos-oxon, were not potent
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inhibitors of AChE in any of the tissues. The more potent inhibitors of AChE, except for
phoxim-oxon, contain a heterocyclic ring in their structure (Figure 1). The presence of
the nitrogen in the ring and the difference in potency is evident when comparing
chlorpyrifos-oxon and ethyl-ronnel-oxon, with chlorpyrifos-oxon (pyridine ring) about
70-fold more potent than ethyl-ronnel-oxon (aromatic ring) in brain and peripheral tissues
(Table 4-5). Acetylcholinesterase IC50s within brain, heart, lung and skeletal muscle for
both the diethyl and dimethyl organophosphates were not different among the three ages
(PND 1, PND 12, and PND 70). The OP IC50s for AChE in the peripheral tissues
typically exhibited greater variability than IC50s in brain tissue with the more potent OPs
usually having less variability (Table 4-5). IC50s for serum AChE were generally
equivalent in the neonates (PND 1) and juveniles (PND 12) but were significantly higher
in adults (PND 70) for all OPs tested except azinphos-methyl-oxon, ethyl ronnel-oxon,
and ethyl cyanophos (Table 6). The addition of a specific inhibitor for CaE in adult
(PND 70) serum reduced the AChE IC50s to values similar to those determined for the
neonates and juveniles (Table 6). No significant differences were determined for
azinphos-methyl-oxon, ethyl ronnel-oxon, and ethyl cyanophos among the three ages
with or without CaE specific inhibitors. Three OPs, dicapthon-oxon, methyl coumaphosoxon and nitropyrifos-oxon, exhibited IC50s that were significantly lower in adults than
the corresponding neonatal and juvenile IC50s (Table 6). Serum BChE IC50s generally
increased with age (Table 7). Butyrylcholinesterase IC50s were significantly higher for
PND 70 serum than PND 12 and PND 1 IC50s for all OPs except azinphos-methyl oxon
and methyl paraoxon. Serum BChE was more sensitive to the diethyl OPs than the
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dimethyl OPs, as evidenced by the greater potency of the diethyl OPs. Azinphos-methyloxon and methyl coumaphos-oxon were not good inhibitors of serum BChE (Table 7).
IC50s for hepatic CaE generally increased with age (Table 8). The hepatic CaE
IC50s for methyl paraoxon, methyl coumaphos-oxon, chlorpyrifos-oxon and ethyl ronneloxon, were significantly higher for the PND 12 rats than the PND 1 rats. Hepatic IC50s
were significantly higher for PND 70 rats compared to PND 1 rats for paraoxon, ethyl
ronnel-oxon, diazoxon, and nitropyrifos-oxon. Additionally, CaE IC50s were
significantly higher from livers of PND 70 rats compared to PND 12 rats for methyl
paraoxon, methyl coumaphos-oxon, and chlorpyrifos-oxon. Because of low activity and
limited sample volume, CaE IC50s were not measured in serum from neonatal rats (PND
1). IC50s for serum CaE generally increased with age from PND 12 to PND 70 with IC50s
for methyl paraoxon, paraoxon and chlorpyrifos-oxon from PND 70 rats significantly
higher than those from PND 12s. Hepatic and serum CaEs were more sensitive to the
diethyl OPs than the dimethyl OP oxons, as evidenced by the greater potency from the
diethyl OPs in PND 70 (highest CaE activity) liver and serum. The two most potent CaE
inhibitors were chlorpyrifos-oxon and ethyl ronnel-oxon both with chlorinated rings in
their structures.
Discussion
Acetylcholinesterase IC50s for the twelve organophosphates (OPs) in this study
suggest that there is no age-related difference in the inhibitory potential toward AChE in
the rat brain. Similar results were observed for the AChE IC50s in heart, lung and skeletal
muscle. These results were not surprising with AChE having been determined to be from
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a single gene product (Massoulié et al., 2008). The decision to measure IC50s in
equivalent tissue concentrations and not activity levels within a tissue could mean the
number of enzyme active sites were not the same among the ages, which could result in
slightly different IC50s. The diethyl OPs were generally more potent inhibitors of AChE
than the dimethyl OPs, except for the two model compounds and diazoxon. Diazoxon
was observed to be particularly unstable as well as it has a propensity to adhere to glass,
which could account for the lower potency compared to the other diethyl insecticidal
OPs. Acetylcholinesterase appears to be more sensitive to diethyl OPs containing
heterocyclic rings in their structure compared to OPs containing aromatic rings, except
for phoxim-oxon which is an equally good inhibitor. For most of the OP compounds,
slight increases in IC50s were observed with age but did not reach significance. These
results are in agreement with previously reported data for chlorpyrifos-oxon (Mortensen
et al., 1996; Atterberry et al., 1997) in rat brain. There were significant differences in
serum AChE IC50s between the adult (PND 70) and young rats (PND 1 or PND12) for 9
of the 12 OPs tested; however, these differences were negated when a specific CaE
inhibitor was included in the assays, indicating that the higher IC50s in the adult rat serum
are most likely because of CaEs stoichiometrically binding circulating OP and preventing
the inhibition of AChE. This correlates with the increase in CaE activity in the serum in
adult rats compared to the juveniles and neonates.
Studies from our laboratory and others have shown that young rats have lower
CaE activity than adults (Moser et al., 1998; Atterberry et al., 1997). Atterberry et al.
(1997) reported hepatic CaE activities in young rats (PND 3) were about 5-fold lower
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than adult rats (PND 70). Moser et al. (1998) also reported similar differences (6-fold
increase) for serum CaE activity between the PND 3 and PND 70 rats. Atterberry et al.
(1997) also showed a decrease in sensitivity in vivo to two OP insecticides, chlorpyrifos
and parathion, paralleled the maturation of liver CaE with age in rats. This suggests that
the age-related differences in acute toxicity levels that are associated with some
organophosphate compounds are likely due to either a difference in the rate of CYP450mediated metabolism to their bioactive metabolite or more likely to differences in the
detoxication of the oxons by non-target esterases such as carboxylesterases and Aesterases (paraoxonases) (Gagne and Brodeur, 1972; Chambers et al., 1990; Forsyth and
Chambers, 1989; Fukuto et al., 1990; Pope et al., 1991; Ma and Chambers, 1995; Pond et
al., 1995; Atterberry et al., 1997; Moser et al., 1998). This hypothesis is supported by
the data within this study.
The lower serum and hepatic CaE IC50s, reported here, suggests that younger rats
may be more sensitive to some OPs. This may be a result of lower concentrations of CaE
and/or sensitivity of enzymes in younger ages. The age-related increase in serum AChE
IC50s without a specific inhibitor for carboxylesterases (CaE activity present) further
exhibits the protection CaE can provide the target enzyme (AChE) to OPs. As with
AChE, the structure of the OP can affect the inhibitory potential for CaE. Data within
this study suggest that the diethyl OPs are much better inhibitors of CaE than the
dimethyl OPs. The in vitro data from this study correlate with data from other studies
comparing OP potencies for AChE in vitro and toxicities in vivo (Chambers et al., 1990;
Chambers and Carr, 1993; Chambers et al., 1994). The greater detoxication of many
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diethyl OPs helps explain the discrepancies between the AChE inhibitory potencies and
acute toxicity. For example, chlorpyrifos-oxon (a diethyl OP) is a better inhibitor of
AChE than methyl paraoxon or azinphos-methyl-oxon (dimethyl OPs); however,
chlorpyrifos has a higher rat oral LD50 (96 mg/kg) than azinphos-methyl (12 mg/kg) or
methyl parathion (6 mg/kg). Chlorpyrifos-oxon has a much lower CaE IC50 than
azinphos-methyl-oxon or methyl paraoxon, indicating a higher affinity for the CaE and
thus potentially scavenging a greater amount from circulation resulting in greater
protection. All the diethyl OPs exhibited IC50s in the low nanomolar range in both liver
and serum indicating the high affinity for CaE and potential for greater detoxication.
Pope et al. (1991) showed faster peak inhibition of brain cholinesterase activity in
neonates compared to adults following chlorpyrifos exposure. This was most likely the
result of lower detoxication (CaE and paraoxonase) enzymes in the neonates allowing
more chlorpyrifos-oxon to reach the target brain AChE. Exposures to high acute levels
or chronic lower levels of some OPs can saturate the detoxication enzymes resulting in
substantial brain AChE inhibition and toxicity (Chambers and Chambers, 1990). While
detoxication of some of the OPs by CaEs and paraoxonases provides substantial
protection especially in mature animals, studies have shown that inhibition of the target
enzyme, brain AChE, can occur prior to saturation of CaEs (Chambers and Chambers,
1990). Chambers et al. (1991) showed that CYP-mediated bioactivation for parathion
can occur in the target site organ (brain). Although the CYP activity in the brain was
reported to be low, the bioactivation to paraoxon was appreciable enough to produce
brain AChE inhibition. Paraoxonase can hydrolyze some OPs very efficiently, such as
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chlorpyrifos-oxon, but typically is more important in chronic lower level OP exposures
(Pond et al., 1995; Furlong et al., 1989; Atterberry et al., 1997; Tang and Chambers,
1999). The lower levels of paraoxonase activity in juveniles can be important in the
increased toxicity of some OPs in young animals (Atterberry et al., 1997; Li et al., 1997;
Karanth and Pope, 2000).
In addition to CaE and paraoxonase detoxication of OPs, the stoichiometric
inhibition of BChE by OPs can reduce OP toxicity by scavenging OP molecules prior to
reaching the target enzyme, AChE. OPs with higher affinities for BChE than AChE
could be detoxified more efficiently than OPs that have a higher affinity for AChE.
Adult rat serum BChE IC50s for the dimethyl OPs tested within this study were higher
than serum AChE IC50s indicating that the dimethyl compounds have a greater affinity
for AChE than BChE. This suggests that BChE would not scavenge dimethyl OPs well;
therefore, BChE would not afford much protection from OPs with these structural
characteristics. The reverse was observed for the diethyl OPs with adult rat serum BChE
IC50s lower than adult rat serum AChE IC50s indicating greater diethyl OP oxon affinity
for BChE and subsequently the potential for increased detoxication. All of the diethyl
OPs tested exhibited significantly higher BChE IC50s in adults than neonates and
juveniles. This decrease in potency is most likely because of the maturation of BChE
with age. Only one of the dimethyl OPs, dicapthon-oxon, tested within this study
exhibited significantly higher IC50s in adult rat serum compared to neonates and
juveniles, although the IC50s for the other three dimethyl OPs were trending higher with
increasing age. Similar to AChE, serum BChE appears to be slightly more sensitive to
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diethyl oxons containing heterocyclic rings in their structure compared to OPs containing
aromatic rings. Li et al. (2000) reported higher BChE concentration was higher in adult
heart tissue compared to neonates and subsequently, Howard et al. (2007) showed that
BChE activity in neonatal rat heart was more sensitive to inhibition by chlorpyrifos-oxon
than activity in adult rat heart tissue. The stoichiometric inhibition of BChE by OPs can
result in saturation of the enzyme which can lead to increased toxicity in high level
exposures or chronic lower level exposures. Similarly, lower levels of BChE activity in
the serum of younger animals may increase their susceptibility to OP toxicity.
Conclusion
The OP compounds investigated in this in vitro study displayed a wide range of
inhibitory potential toward the target enzyme, AChE, as well as non-target detoxication
enzymes, BChE and CaE, ranging over several orders of magnitude. Generally, the
diethyl insecticidal oxons were more potent inhibitors than the dimethyl insecticidal
oxons, which is in contrast to the acute toxicity of some of the parent insecticides. This
discrepancy may be partially explained by the fact that many of the dimethyl compounds
are poor inhibitors of the non-target esterases responsible for detoxication of OPs. This
study and others have reported age-related differences in the in vitro potency of some OP
compounds in tissues from rats (Mortensen et al., 1996, 1998; Moser et al., 2016). In
vitro studies can provide valuable insights into the metabolism and detoxication pathways
of OPs to help explain the age-related differences in acute OP toxicity in vivo, that have
been reported for many years (Brodeur and DuBois, 1963; Benke and Murphy, 1975;
Gaines and Linder, 1986; Pope et al., 1991; Atterberry et al., 1997; Moser et al., 1998).
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Although the toxicological target for OPs is well described, the differences in
bioactivation and detoxication with respect to age and sex must be considered when
assessing risk. In vivo challenges of OPs are ultimately needed to address these
differences; however, in vitro studies such as the one reported here can provide
information (potency, kinetic rate constants, etc.) for the biochemical processes that can
then be used in developing predictive models that, once validated, can reduce or replace
the number of in vivo studies.
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Table 2.1

Organophosphate compounds and their corresponding toxicities

Organophosphate Oxon (active
metabolite)
Azinphos-methyl-oxon (AZMxn)

Commercial
Pesticide or Model
Compound
Azinphos-methyl

Rat Oral
LD50
(mg/kg)
12 mg/kg

Methyl paraoxon (MPxn)

Methyl parathion

6 mg/kg

Dicapthon-oxon (DCxn)

Dicapthon

400 mg/kg

Methyl coumaphos-oxon (MCxn)

Model Compound

NA

Paraoxon (Pxn)

Parathion

2 mg/kg

Chlorpyrifos-oxon (CPxn)

Chlorpyrifos

96 mg/kg

Ethyl cyanophos-oxon (Ecxn)

Model Compound

NA

Ethyl ronnel-oxon (Erxn)

Model Compound

NA

Diazoxon (DZxn)

Diazinon

1250 mg/kg

Naftalophos (Nftf)

Naftalophos

140 mg/kg

Nitropyrifos-oxon (NPxn)

Model Compound

NA

Phoxim-oxon (Phxxn)
Phoxim
2000 mg/kg
LD50 values (rat oral) for the commercial organophosphates (parent compound) are
presented as reported in (Meister et al., 1992 or EPA, 2006). NA (not available) = LD50
values have not been determined for model compounds (experimental use only).
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27.0 ± 0.9B

25.4 ± 1.2B

20.6 ± 2.0A

17.9 ± 0.6A

Lung

30.3 ± 1.2B

22.9 ± 0.7A

21.2 ± 0.3A

Skeletal
Muscle

12.9 ± 0.3A

11.4 ± 0.6A

10.4 ± 1.1A

Serum

8.7 ± 0.4C

6.0 ± 0.2A

4.9 ± 0.2A

Serum

BChE
Activities

1154 ± 22C

558 ± 11B

147 ± 10A

Liver

160 ± 7.1C

70 ± 6.3B

20 ± 6.2A

Serum

CaE Activities

Specific activities expressed as nmoles min-1 mgP-1, for AChE, BChE and CaE, means ± SEM of three independent
replications. Means within a tissue not followed by the same letter are significantly different (p<0.05).

98.8 ± 5.2C

22.8 ± 0.7A

79.4 ± 4.8B

PND 12

PND 70

19.9 ± 0.2 A

Heart

43.4 ±7.1A

Brain

AChE Activities

Specific activities for brain, heart, lung, skeletal muscle and serum acetylcholinesterase (AChE), serum
butyrylcholinesterase (BChE), and liver and serum carboxylesterase (CaE) from rats of three ages (post-natal day,
PND 1, 12 and 70).

PND 1

Age

Table 2.2
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Table 2.3

145 ± 0.1A
176 ± 0.1B

96 ± 0.4A
138 ± 0.5B

PND 12

PND 70

149 ± 0.1B

126 ± 0.1A

107 ± 0.1A

Lung

150 ± 1.2A

133 ± 0.9A

121 ± 0.1A

Skeletal
Muscle

109 ± 0.4C

96 ± 0.8B

74 ± 1.1A

Serum

189 ± 0.8C

144 ± 0.7A

135 ± 1.2A

Liver

Protein levels expressed as µg P, for AChE, BChE and CaE, means ± SEM of three independent replications.
Means within a tissue not followed by the same letter are significantly different (p < 0.05).

137 ± 0.3 A

Heart

76 ± 0.9A

Brain

PND 1

Age

Protein µg

Protein levels for brain, heart, lung, skeletal muscle, serum and liver from rats of three ages (post-natal day,
PND 1, 12 and 70).
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PND 1
IC50 (nM)
(95%CI)
430
(252,607)
248
(36,461)
67
(19,113)
955
(832,1077)
156
(115,197)
5
(3,8)
1313
(1116,1510)
717
(704,729)
45
(32,57)
17
(6,27)
54
(44,64)
15
(9,20)

Heart
PND 12
IC50 (nM)
(95%CI)
495
(317,673)
583
(410,757)
84
(46,122)
987
(846,1109)
167
(127,208)
5
(3,7)
1395
(1235,1556)
721
(711,731)
43
(32,53)
11
(7,15)
61
(38,54)
12
(7,16)
PND 70
IC50 (nM)
(95%CI)
212
(33,389)
507
(334,681)
34
(-4,73)
894
(773,1017)
103
(62,143)
3
(1,5)
1040
(880,1241)
708
(706,717)
36
(26,47)
4
(1,7)
36
(28,44)
8
(4,13)

PND 1
IC50 (nM)
(95%CI)
407
(256,558)
455
(307,503)
109
(95,123)
474
(377,571)
69
(60,77)
8
(6,10)
1163
(1038,1387)
652
(618,688)
134
(91,177)
43
(33,52)
46
(29,63)
24
(19,29)

Lung
PND 12
IC50 (nM)
(95%CI)
281
(129,423)
438
(290,586)
100
(86,115)
446
(350,543)
65
(57,74)
7
(5,8)
1217
(993,1443)
687
(652,722)
133
(90,177)
30
(21,39)
49
(32,66)
21
(16,27)
PND 70
IC50 (nM)
(95%CI)
279
(172,430)
158
(8,307)
116
(101,131)
295
(198,391)
54
(45,63)
6
(5,8)
812
(587,1036)
699
(664,735)
221
(177,264)
44
(35,54)
24
(7,41)
21
(15,26)

Skeletal Muscle
PND 1
PND 12
PND 70
IC50 (nM) IC50 (nM) IC50 (nM)
(95%CI)
(95%CI)
(95%CI)
154
159
83
(82,226)
(101,218)
(25,141)
266
243
184
(119,413) (123,363)
(64,305)
82
64
92
(64,101)
(49,78)
(78,107)
250
230
94
(162,348) (161,299)
(25,163)
34
47
50
(9,59)
(26,67)
(29,70)
6
4
9
(4,9)
(2,6)
(6,10)
791
1022
733
(645,937) (876,1169) (587,879)
744
752
773
(726,762) (734,770)
(755,791)
22
38
51
(7,37)
(26,51)
(37,62)
20
17
41
(3,37)
(3,31)
(27,55)
30
29
28
(17,43)
(15,42)
(15,42)
14
12
17
(6,21)
(5,18)
(11,24)

Acetylcholinesterase inhibition by various organophosphates in rat cardiac, pulmonary, and muscle tissue.

IC50s are expressed as means with 95% confidence intervals of three independent replications for each age group. Means for
each compound followed by an * are significantly different (p < 0.05) among ages within a tissue.

Phxxn

NPxn

Nftf

DZxn

Erxn

Ecxn

CPxn

Pxn

MCxn

DCxn

MPxn

AZMxn

Oxon

Table 2.4

Table 2.5

Acetylcholinesterase inhibition by various organophosphates in rat brain.
Brain Acetylcholinesterase

PND 1
PND 12
PND 70
IC50 nM
IC50 nM
IC50 nM
Oxon
(95%CI)
(95%CI)
(95%CI)
115
98
96
AZMxn
(104,125)
(68,109)
(86,107)
165
118
135
MPxn
(132,198)
(85,151)
(102,168)
175
131
139
DCxn
(144,205)
(101,162)
(108,170)
124
109
74
MCxn
(89,160)
(73,144)
(38,109)
32
36
25
Pxn
(24,39)
(28,44)
(16,32)
9
8
8
CPxn
(6,12)
(5,11)
(5,11)
984
925
784
Ecxn
(864,1104)
(805,1045)
(664,904)
622
716
691
Erxn
(515,729)
(609,822)
(583,798)
224
252
273
DZxn
(185,264)
(212,291)
(233,312)
62
75
64
Nftf
(43,81)
(57,94)
(46,83)
40
38
34
NPxn
(29,52)
(26,49)
(23,46)
50
52
43
Phxxn
(38,63)
(39,64)
(30,55)
IC50s are expressed as means with 95% confidence intervals of three independent
replications for each age group. Means for each compound followed by an * are
significantly different (p < 0.05) among ages within a tissue.
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Table 2.6

Acetylcholinesterase inhibition by various organophosphates in rat serum.
Serum Acetylcholinesterase

Serum +
Selective
Inhibitors

PND 1
PND 12
PND 70
PND 70
IC50 nM
IC50 nM
IC50 nM
IC50 nM
Oxon
(95%CI)
(95%CI)
(95%CI)
(95%CI)
117
127
178
232
AZMxn (58,175)
(68,185)
(118,236)
(160,304)
137
114
219*
75
MPxn
(70,163)
(68,161)
(172,265)
(18,131)
94
84
144*
46**
DCxn
(86,101)
(77,92)
(137,152)
(37,55)
217
212
295*
138**
MCxn (195,238)
(191,234)
(273,317)
(110,163)
56
47
106*
48
Pxn
(46,64)
(38,56)
(97,116)
(36,60)
10
10
54*
7
CPxn
(7,13)
(6,13)
(51,57)
(3,11)
1140
1359
1534
1234
ECxn (926,1354) (1144,1573) (1319,1748)
(972,1496)
462
477
490
399
ERxn
(409,515)
(424,530)
(437,543)
(334,463)
157
194
309*
213
DZxn
(127,186)
(164,223)
(280,338)
(177,248)
39
34
67*
32
Nftf
(29,49)
(24,44)
(57,77)
(20,44)
46
51
83*
23**
NPxn
(43,49)
(47,54)
(80,86)
(19,27)
30
31
109*
29
Phxxn
(25,35)
(26,36)
(103,114)
(23,35)
IC50s are expressed as means with 95% confidence intervals of three independent
replications for each age group. Means for each compound followed by an * are
significantly different (p < 0.05) among ages within a tissue. Serum + selective inhibitors
for CaE (SCPP) and BChE (ethopropazine).
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Table 2.7

Butyrylcholinesterase inhibition by various organophosphates in rat
serum.
Serum Butyrylcholinesterase

PND 1
PND 12
PND 70
IC50 nM
IC50 nM
IC50 nM
Oxon
(95%CI)
(95%CI)
(95%CI)
1051
1259
1433
AZMxn (931,1382) (1181,1337) (1176,1691)
389
381
394
MPxn
(386,392)
(357,406)
(337,452)
58
57
185*
DCxn
(55,62)
(53,61)
(179,192)
1223
1212
1469
MCxn (1137,1308) (1191,1234) (1116,1821)
47
52
76*
Pxn
(46,48)
(50,54)
(58,94)
6
7
39*
CPxn
(5,7)
(6,7)
(30,49)
208
224
339*
ECxn
(167,249)
(180,268)
(282,396)
2
7
35*
ERxn
(1,3)
(3,8)
(23,48)
8
10
31*
DZxn
(7,9)
(9,11)
(30,33)
5
7
30*
Nftf
(4,6)
(6,7)
(37,43)
15
14
64*
NPxn
(14,16)
(13,15)
(56,73)
2
31*
60**
Phxxn
(1,3)
(26,36)
(57,64)
IC50s are expressed as means with 95% confidence intervals of three independent
replications for each age group. Means for each compound followed by an * are
significantly different (p < 0.05) among ages within a tissue.
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Table 2.8

Carboxylesterase inhibition by various organophosphates in rat hepatic
tissue or serum.
Carboxylesterase
Liver IC50 (nM)
(95%CI)

Oxon

Serum IC50 (nM)
(95%CI)

PND 1
PND 12
PND 70
PND 12
PND 70
182
190
337
213
282
AZMxn
(158,206)
(98,282)
(257,417)
(70,359)
(272,321)
0.6
3.2*
309**
49
80*
MPxn
(0.4,0.9)
(2.7,3.6)
(260,357)
(37,61)
(73,87)
55
61
66
61
81
DCxn
(27,83)
(32,92)
(28,105)
(27,94)
(74,87)
49
89*
640**
31
35
MCxn
(36,62)
(64,113)
(550,730)
(27,34)
(25,44)
0.13
0.14
1.6*
2.5
4.3*
Pxn
(0.1,0.2)
(0.1,0.2)
(0.5,2.8)
(1.8,3.1)
(3.5,5.1)
0.02
0.05*
0.16**
0.30
0.70*
CPxn
(0.01,0.02)
(0.04,0.05)
(0.06,0.27)
(0.2,0.3)
(0.6,0.8)
0.2
0.2
0.45
0.17
0.21
ECxn
(0.1,0.3)
(0.1,0.2)
(0.2,0.7)
(0.01,0.33)
(0.08,0.35)
0.04
0.09*
0.20*
0.35
0.49
ERxn
(0.03,0.06)
(0.08,0.1)
(0.1,0.3)
(0.24,0.46)
(0.39,0.6)
0.2
0.3
1.1*
0.3
0.5
DZxn
(0.1,0.3)
(0.2,0.3)
(0.8,1.3)
(0.2,0.5)
(0.4,0.6)
5.0
5.3
5.7
1.1
1.3
Nftf
(3.7,6.3)
(4.9,5.6)
(5.0,6.5)
(0.7,1.5)
(1.1,1.6)
10
17
30*
11
16
NPxn
(5,15)
(11,23)
(25,34)
(6,16)
(8,24)
0.2
0.2
0.4
0.9
1.1
Phxxn
(0.1,0.3)
(0.2,0.3)
(0.3,0.5)
(0.6,1.2)
(0.7,1.5)
IC50s are expressed as means with 95% confidence intervals of three independent
replications for each age group. Means for each compound followed by an * are
significantly different (p<0.05) among ages within a tissue.
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Figure 2.1

Chemical structures of 12 organophosphates/oxons.
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CHAPTER III
METABOLISM OF MALATHION BY HUMAN AND RAT HEPATIC
MICROSOMES
Introduction
Malathion (O,O-dimethyl dithiophosphate of diethyl mercaptosuccinate; Figure 1)
is one of the most extensively used organophosphate (OP) insecticides in the United
States and throughout the world. First synthesized in 1956, malathion has continuously
been heavily used because of its insecticidal properties combined with its low
mammalian toxicity (rat oral LD50 > 1000 mg/kg) (Terrell, 1979; Fisher, 1991; Meister,
1992). Malathion is a non-systemic pesticide used to control a wide range of sucking and
chewing insects in a variety of agricultural applications including crops and livestock. In
addition, malathion is heavily used for public health in the control of vector-borne
diseases such as the mosquito borne diseases malaria, zika, and dengue (ATSDR, 2017;
US EPA, 2006). Depending on the application, malathion can be formulated as a dust,
wettable powder, emulsifiable concentrate, or a liquid (US EPA, 2006). The heavy usage
of this OP worldwide requires intensive risk assessment by regulatory agencies, such as
the United States Environmental Protection Agency.
The primary toxic mechanism of action of malathion is via inhibition of the serine
esterase, acetylcholinesterase (AChE, EC 3.1.1.7); this requires bioactivation of
malathion by cytochrome P450 (CYP) to the active anticholinesterase metabolite,
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malaoxon (Cohen, 1984; Forsyth and Chambers, 1989; Thompson et al., 1989; Fukuto,
1990; Buratti et al., 2005). The mammalian metabolism of malathion is very complex
with bioactivation and detoxication processes occurring simultaneously (Dauterman and
Main, 1966; Buratti et al., 2005). Talcott et al. (1979) reported that technical grade
malathion can have impurities, such as isomalathion, that can affect its metabolism and
toxicity. Malathion can be inactivated by glutathione S-transferases, although this is a
minor pathway (Dauterman and Main, 1966; Talcott, 1979; Ketterman et al., 1987). The
primary detoxication pathway involves the enzyme, carboxylesterase (CaE; EC 3.1.1.1),
which is capable of degrading both the parent insecticide, malathion, and its
anticholinesterase metabolite, malaoxon (Figure 1) (Casida, 1961; Main and Braid, 1962;
Dauterman and Main; 1966). Malathion, containing carboxylic esters in its structure, can
be catalytically hydrolyzed by CaE to a monocarboxylic acid (MCA) which can be
further metabolized to a dicarboxylic acid (DCA) (Figure 2) (Seume and O'Brien, 1960;
Main and Braid, 1962). The catalytic hydrolysis of malathion by CaE is very efficient
and the MCA and DCA products are both considered non-toxic metabolites; therefore,
this is considered an effective detoxication pathway (Main and Braid, 1962; Buratti et al.,
2005).
Malaoxon, the anticholinesterase metabolite of malathion, can also
stoichiometrically inhibit CaE decreasing the amount of malaoxon available to inhibit the
target enzyme, AChE (Murphy and Dubois, 1957; Main and Braid, 1962). The
detoxication potential via CaE of both malathion and malaoxon is a major factor in its
low mammalian acute toxicity, rat oral LD50 > 1 g/kg (Casida, 1961; Main and Braid,
1962; Dauterman and Main; 1966). Main and Braid (1962) reported an increase of about
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50-fold in the LD50 for malathion in rats pretreated with tri-o-tolyl phosphate, TOTP, a
potent CaE inhibitor. This can be especially important in young animals that have been
shown to have lower levels of CaE activity (Maxwell, 1992; Morgan et al., 1994;
Atterberry et al., 1997). The abundance of CaE in adult rat liver and serum provides the
potential for substantial degradation of many OPs. The absence of CaE activity in human
serum (Main and Braid, 1962; Li et al., 2005) may reduce their overall detoxication
capacity compared to the rat; however, humans possess large amounts of CaE in other
tissues, especially the liver (Zhu et al., 2009; Moser et al., 2016). Catalytic hydrolysis of
some OP oxons by paraoxonase (PON), a calcium dependent hydrolase, can offer
additional protection from OP intoxication (depending on the OP structure).
Paraoxonase-mediated degradation of malaoxon has been proposed to be a potential
mechanism in the detoxication of malaoxon; however, the validity of this detoxication
pathway has not been confirmed. The maturation in OP detoxication enzymes (CaE and
PON) with age has been well documented in animal models (Atterberry et al., 1997;
Padilla et al., 2000) and humans, although activities in humans appear to be more
variable with age (Cole et al., 2003; Pope et al., 2005; Yang et al., 2005; Moser and
Padilla, 2016).
The development of physiologically based pharmacokinetic (PBPK) models has
become very valuable in evaluating risk for compounds with known toxicological targets
(Reitz et al., 1988; Timchalk et al., 2002; Poet et al., 2004; Marino et al., 2006; Yang and
Lu, 2006). These models use a series of differential equations to predict toxicity from a
given exposure. Construction and validation of these mathematical models requires
kinetic parameters generated from laboratory experiments for the target organs and
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processes involved in the absorption, distribution, metabolism and excretion (ADME) of
a given compound (Reddy, 2005). Kinetic constants for the bioactivation (desulfuration)
and detoxication processes for malathion and its active metabolite, malaoxon, will be
important for the construction of predictive pharmacokinetic models. Regulatory
agencies have used PBPK models for other OPs in risk assessments for that compound
(Timchalk et al., 2002; Knaak et al., 2004); however, the lack of a validated PBPK model
for malathion is an impairment to the extrapolation from animal model data to human
risk. The determination of kinetic rates for the degradation of malathion and malaoxon
via carboxylesterases will be difficult with both detoxication processes occurring
essentially simultaneously. This is further confounded by the stoichiometric inhibition of
CaE by malaoxon, thus inactivating that CaE molecule preventing it from catalytically
hydrolyzing malathion (Murphy and Dubois, 1957; Main and Braid, 1962). In addition,
the maturation of enzymes responsible for activation (CYP) and detoxication (CaE and
PON) with age must be considered when modeling the pharmacokinetics and
pharmacodynamics of OPs, such as malathion (Timchalk et al., 2002; Clewell et al.,
2004).
The majority of the risk assessment for OP compounds, such as malathion, has
been based on data generated in animal models and extrapolated to humans (Timchalk et
al., 2002; Knaak et al., 2004). In addition, human biomarker data following occupational
or residential exposures has been used to refine and validate risk models and risk
assessments (Bradman et al., 2003; Wessels et al., 2003; Barr and Angerer, 2006). The
Federal Food, Drug, and Cosmetic Act (FFDCA), as amended by the Food Quality
Protection Act of 1996, required the addition of uncertainty factors to add an additional
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level of protection for infants and children which lowers the tolerances of exposure for
these pesticides. Uncertainty factors are often included in risk assessments to account for
differences in animals and humans (interspecies, 10x) and for differences in sensitive
populations (intraspecies, 10x), such as children (US EPA, 1993, 1996; Dourson et al.,
1996; Mileson et al., 1998; Yang and Lu, 2006). FQPA required an additional tenfold
(10x) safety factor to account for differences with respect to exposure and toxicity in
infants and children. FFDCA authorizes EPA to reduce the 10x FQPA safety factor only
if sufficient data demonstrate that the margin of exposure is adequate (US EPA, 2009).
The determination of kinetic parameters for the metabolism of malathion will be
important in assessing if the additional levels of safety are necessary for interspecies and
intraspecies differences.
The current investigation examined the metabolism of malathion using individual
rat and human liver microsomes. Mammalian livers contain high levels of the enzymes
responsible for both the bioactivation (CYP) and detoxication (CYP, CaE and PON) of
OPs (Sultatos and Murphy, 1983; Chambers et al., 1990; Fukuto et al., 1990; Pond et al.,
1990; Chambers and Carr, 1993; Atterberry et al., 1997). The kinetic rate constants, Vmax
and Kmapp, for CYP-mediated bioactivation of malathion were determined in vitro using
microsomes prepared from adult rats of both sexes and humans of both sexes and various
ages and ethnicities. In addition, CaE activities and detoxication potential were
determined for the same microsomes. Finally, the potential hydrolysis of malaoxon via
paraoxonase was investigated as a detoxication pathway. The determination of kinetic
rate constants and pathways of detoxication in both rat and human tissues will be useful
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in the development of pharmacokinetic models for malathion and ultimately for risk
assessment.

Materials and Methods
Chemicals
Malathion and its oxon metabolite, malaoxon, were supplied from FMC, Inc.
Structures were confirmed by nuclear magnetic resonance (NMR) at FMC and the
Department of Chemistry at Mississippi State University. All other reagent grade
chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) or Thermo-Fisher
Scientific (Waltham, MA). A selective carboxylesterase inhibitor saligenin cyclic
phenylphosphonate (SCPP) was synthesized by Dr. Howard Chambers at Mississippi
State University using standard procedures from commercially available intermediates
(Chambers and Chambers, 1989) and purity was determined to be greater than 98% by
NMR by the Department of Chemistry at Mississippi State University.
Human Microsomes
Human liver microsomes (archived frozen samples) were purchased from Sekisui
Xenotech, LLC (Kansas City, KS). Twenty-seven individual microsomal samples were
obtained that were from humans of both sexes, and of several races/ethnicities and span
an age range of 0.04-75 years. In addition, a pooled microsomal sample prepared from
200 human livers was purchased to optimize assay conditions. All human liver
microsomes were adjusted to 20 mg protein (P)/ml by the vendor.
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Animals
Adult male (6) and female (6) Sprague Dawley-derived rats (post-natal day 70,
PND 70; approximately 225-300 g) were purchased from Envigo, Inc. and housed in
AAALAC accredited facilities in the College of Veterinary Medicine at Mississippi State
University with temperature-controlled environments and 12 h dark-light cycle. Standard
lab chow and tap water were provided ad libitum. All animal procedures received prior
approval from the Mississippi State University Animal Care and Use Committee.
Rat Microsomes
Rat liver was collected from adult (PND 70) male and female rats, rinsed with
0.9% saline, immediately snap-frozen in liquid nitrogen and stored at -80ºC. Rat liver
microsomes were prepared according to established procedures in our laboratories
(Forsyth and Chambers, 1989). Briefly, a similar section of rat liver (0.5 g) was
homogenized in 0.05M Tris-HCl buffer plus 0.15M KCl (pH 7.4 at 37ºC). Liver
homogenates were centrifuged at 17,000 g for 15 min followed by ultracentrifugation of
the resulting supernatant (110,000 g for 60 min). The supernatant was discarded and the
microsomal pellet was suspended in 250 mM sucrose and stored at -80ºC until assayed
(suspension and storage conditions were equivalent to the purchased human
microsomes).
Kinetics of Malathion Activation (Desulfuration)
Bioactivation (desulfuration) of malathion, which is CYP-mediated and occurs
primarily in the liver, to malaoxon was quantified indirectly by the inhibition of an
exogenous source of AChE (purified electric eel; FC, 0.2 U/ml) following incubation of
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the microsomal fraction with malathion (Ma and Chambers, 1994; Buratti et al., 2005).
The use of the AChE “trap” to capture the active metabolite, oxon, as it is being produced
allows for detection at very low concentrations before appreciable degradation of the
oxon can occur. Increasing concentrations of malathion were incubated with the dilute
liver microsomes in order to establish curves to calculate the kinetic values, Kmapp and
Vmax. For this assay, microsomal pellets were thawed and resuspended in 0.05M TrisHCl buffer plus 0.005M MgCl2 (pH 7.4 at 37ºC). The resuspension was diluted to 1 mg
equivalent/ml buffer. One hundred µl of the diluted microsomal resuspension was added
to three borosilicate glass test tubes to which 100 µl of diluted electric eel AChE was also
added and placed on ice. Eserine sulfate, 50 µl (FC, 0.2 mM), was added to the first tube
to inhibit AChE and correct for non-enzymatic hydrolysis. To a second tube, a tissue
blank, 50 µl of 0.05M Tris-HCl buffer plus 0.005M MgCl2 (pH 7.4 at 37ºC) was added.
To additional sample tubes (for each of eight concentrations of malathion), 50 µl of a
NADPH generating system was added. The generating system consisted of 0.01 M
glucose-6-phosphate, 0.001 M nicotinamide adenine dinucleotide phosphate) and 0.18
unit of glucose-6-phosphate dehydrogenase. Tubes were vortexed and placed in a
shaking water bath pre-heated to 37ºC for 2 min. The reaction was initiated by the
addition of 5 µl of each concentration of malathion in EtOH vehicle to all tubes. The
tubes were vortexed and incubated in the water bath for 30 min. Following the
incubation period, cholinesterase activity was monitored spectrophotometrically using a
modified Ellman et al. (1961) assay (Chambers et al., 1988); 1.75 ml of 0.05M Tris-HCl
buffer (pH 7.4 at 37ºC) plus acetylthiocholine iodide (ATCh, FC, 1 mM) was added,
vortexed and incubated for an additional 10 min to react with any uninhibited AChE.
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The reaction was terminated and color was developed using 250 μl of a 5% sodium
dodecyl sulfate/0.024 M 5,5’-dithiobis(nitrobenzoic acid) (SDS/DTNB) mixture (4:1).
Absorbance was measured at 412 nm using a spectrophotometer.
Malaoxon generated was quantified from a standard curve of malaoxon
concentration versus electric eel AChE inhibition. A range of concentrations were used to
result in AChE inhibition between 10% and 90%. Linear regression analysis was
performed of the plot of the logit of percent inhibition versus log10 oxon concentration.
The best-fit line was drawn using points corresponding to the 10-90% AChE inhibition
range. The standard curve was run three independent times using a unique set of reagents
and the data were averaged to produce a single standard curve to use for quantification of
malathion bioactivation to malaoxon (Figure 3). This assay provides an advantage over
some analytical chemistry techniques such as high-performance liquid chromatography,
HPLC, that can be expensive, time consuming, require extraction of the metabolites
increasing the likelihood of loss during extraction, and may not capture the oxon before
degradation occurs.
Carboxylesterase Degradation of Malathion
In addition to the standard desulfuration assay, a single high concentration of
malathion (200 µM) was incubated with each dilute microsome with and without pretreatment with a selective CaE inhibitor, SCPP, to assess CaE-mediated degradation
using AChE inhibition as an endpoint. The assay procedure was identical to the
desulfuration assay previously described with the addition of a pre-incubation step (10
min in a shaking water bath at 37ºC) with SCPP (FC, 50 nM) or EtOH vehicle.
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Carboxylesterase Degradation of Malaoxon
To assess the capacity of each rat and human hepatic microsome to degrade
malaoxon by CaEs, an indirect measurement of the CaE-mediated degradation was
employed. Parallel dilute hepatic microsomal preparations (0.25 ml, equivalent to the
desulfuration assays) were pre-incubated with or without a specific CaE inhibitor, SCPP
(FC, 50 nM in EtOH vehicle), for 10 min in a shaking water bath at 37ºC. Following preincubation, one of each of five concentrations of malaoxon in EtOH vehicle or EtOH
vehicle were added, vortexed and incubated for 15 min. Malaoxon degradation was
evaluated indirectly using the inhibition of an exogenous source of AChE (purified
electric eel) as an endpoint. Eel AChE (FC, 0.2 U/mL) diluted in 1.75 ml of 0.05M TrisHCl buffer (pH 7.4 at 37ºC), was added, vortexed and incubated for an additional 15 min
to allow unbound malaoxon to inhibit AChE. Tubes (blanks) containing eserine sulfate
(FC, 10 µM) were included in the assay to inhibit AChE and correct for non-enzymatic
hydrolysis. The reaction was terminated and color was developed using 250 μl of a 5%
sodium dodecyl sulfate/0.024M 5,5’-dithiobis(nitrobenzoic acid) (SDS/DTNB) mixture
(4:1). Absorbance was measured at 412 nm using a spectrophotometer. Percent
inhibition of control (EtOH vehicle) absorbance was calculated for each concentration.
IC50 (AChE) values were determined by linear regression analysis of the plot of the logit
of percent inhibition versus log10 oxon concentration. The best-fit line was drawn using
points corresponding to the 10-90% AChE inhibition range and the equation of the bestfit line was solved for the x-intercept to determine the IC50. The difference in the SCPP
treated and the non-SCPP treated AChE IC50s was determined as an index of CaE
degradation of malaoxon.
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Carboxylesterase Activities of Rat and Human Microsomes
Liver microsomes were diluted in 0.05M Tris-HCl buffer (pH 7.4 at 37oC) and
assayed according to the method of Chambers et al. (1990) using p-nitrophenyl valerate
(pNPV) as the substrate for CaE. To determine CaE activity for each rat and human
microsome, dilute homogenates (FC, 5 µg P/ml; 2 ml total assay volume) were vortexed
and placed in a shaking water bath preheated to 37ºC. Tubes (blanks) containing
paraoxon (FC, 10 µM) were included in the assay to inhibit CaE and correct for nonenzymatic hydrolysis. For each microsome, triplicate subsamples as well as duplicate
paraoxon blanks were assayed. Following an initial incubation of 15 min, 20 µl of pNPV
(FC, 500 µM) in ethanol vehicle was added as a substrate for the remaining uninhibited
CaE and was incubated for an additional 15 min. The reaction was terminated with 500
μl of a 2% SDS/2% Tris-base mixture. Absorbance was measured at 405 nm using a
spectrophotometer.
Paraoxonase Activities of Rat and Human Microsomes
The active metabolite malaoxon was not expected to be degraded (hydrolyzed) by
paraoxonase (PON1), but this was investigated indirectly according to the method of
Chambers et al. (1994). The indirect method involves the inhibition of an exogenous
AChE source (electric eel) by oxon undegraded by paraoxonase. Individual rat or human
liver microsomal suspensions (5 mg/ml) were added to two sets of tubes containing either
1 mM CaCl2 or 1 mM EDTA (assay volume of 2 ml). SCPP (FC, 50 nM) was added to
liver preparations to inhibit CaE. Malaoxon (FC, 500 nM) was incubated with dilute
microsomes with and without calcium (stimulates paraoxonase activity) or EDTA
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(chelates calcium, inhibiting paraoxonase activity). Eserine sulfate was added to two
additional tubes to serve as a blank by inhibiting AChE activity and correcting for nonAChE hydrolysis. Reaction mixtures were incubated 15 min in a shaking water bath at
37C followed by the addition of eel AChE (FC, 0.2 U/mL) diluted in 1.75 ml of 0.05M
Tris-HCl buffer (pH 7.4 at 37ºC) + 1 mM EDTA to terminate any paraoxonase activity.
Tubes were incubated for an additional 15 min. Acetylthiocholine iodide was added (as a
substrate for the uninhibited AChE; 1 mM FC), and incubated for 15 min. The reaction
was terminated and color was developed using 250 μl of a 5% sodium dodecyl
sulfate/0.024M 5,5’-dithiobis(nitrobenzoic acid) (SDS/DTNB) mixture (4:1).
Absorbance was measured at 412 nm using a spectrophotometer. The amount of
malaoxon hydrolyzed was quantified through the inhibition of AChE by oxon not
degraded by paraoxonase. The percent inhibitions for EDTA- and CaCl2 -containing
tubes were subtracted to determine the amount of oxon hydrolyzed by paraoxonase.
Calculations for Bioactivation of Malathion
The kinetic rates for malathion activation (desulfuration) were calculated
according to concepts developed by Leonor Michaelis and Maud Menten, so called
Michaelis-Menten kinetics. The widely used Michaelis-Menten equation derived from
their work follows a mechanism in which substrate binds reversibly to an enzyme to form
an enzyme-substrate complex, which then reacts irreversibly and generates a product and
the free enzyme (Michaelis and Menten, 1913; Goody and Johnson, 2011). This equation
was used to calculate the maximum velocity (Vmax) and the apparent substrate affinity
(Kmapp) for the activation (desulfuration) of malathion to its anticholinesterase metabolite,
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malaoxon. The Vmax and Kmapp for the CYP-mediated bioactivation of malathion was
calculated from Lineweaver Burk plots of the reciprocals of the substrate (malathion)
concentration versus velocity of malaoxon production (Figure 4), as previously
performed for other OPs (Ma and Chambers, 1994, 1995). Data were plotted using
SigmaPlot 13 software to calculate Vmax and Kmapp for both rat and human microsomes.

For each rat and human liver microsome, the maximum velocity (Vmax) of CYP
production of malaoxon was calculated as described in Equation 1 below:

𝑉𝑚𝑎𝑥[𝑆]

(1)

𝑣 = [𝐾𝑚𝑎𝑝𝑝]+[𝑆]

Using the linear regression of the reciprocals of malathion concentration vs. malaoxon
produced per min (Lineweaver Burk; double reciprocal plot, Figure 4) an equation for a
line could be derived and used to determine the necessary kinetic values (Vmax and Kmapp).
From the line equation (Equation 2) the kinetic values are determined with the
slope equal to Kmapp/Vmax, the y-intercept equal to 1/Vmax, (Kitz and Wilson, 1962; Ma and
Chambers, 1995).

(2)

𝑦 = 𝑚𝑥 + 𝑏
𝑆𝑙𝑜𝑝𝑒 𝑚 =

𝐾𝑚𝑎𝑝𝑝
𝑉𝑚𝑎𝑥

𝑦 − 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 (𝑏) =
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1
𝑉𝑚𝑎𝑥

𝑥 − 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 = −

1
𝐾𝑚𝑎𝑝𝑝

Statistical Analysis
Bioactivation data and carboxylesterase data were analyzed using
SigmaPlot/SigmaStat 13 software on a PC. Differences in mean values for human and rat
liver microsomes as well as differences in sexes within a species were determined using
the Student’s T-Test, with a level of p ≤ 0.05 used to conclude a significant difference in
means. Differences among ages for bioactivation and carboxylesterase activities were
analyzed using Pearson Product Moment Correlation.
Results
To investigate interspecies differences in the bioactivation of malathion to
malaoxon, twenty-seven individual human liver microsomes (8 females and 19 males)
ranging in age from 2 weeks to 75 years were purchased (Xenotech, LLC) for
comparison to microsomes prepared in house from male and female adult rats. The
human liver microsomes were adjusted by the vendor to equivalent protein
concentrations (20 mg/ml). For consistency, the rat liver microsomes were also adjusted
to equivalent protein concentrations (20 mg/ml). Total CYP content for 23 of the human
liver microsomes was determined and supplied by the vendor (Table 2) as well as
individual CYP isozyme content for some of the microsomes. Total CYP content was
not determined for the rat microsomes. Eight different concentrations of malathion (50
µM to 2000 µM) were tested for CYP-mediated bioactivation to the anticholinesterase
metabolite malaoxon for both rat and human hepatic microsomes using an indirect
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measurement of malaoxon produced (inhibition of an exogenous source of AChE).
Malathion in its parent form did not inhibit the AChE trap at any of the concentrations
tested. The maximum velocity (Vmax) and an index of substrate affinity (Kmapp) for
malathion desulfuration were calculated from Lineweaver Burk (double-reciprocal) plots
that were plotted using SigmaPlot 13 software. The mean r2 values for the Lineweaver
Burk plots were 0.930 for the human microsomes and 0.955 for the rat microsomes
(Table 1-2). The data were also plotted using a hyperbolic equation; however, the data
for some of the microsomes did not fit the equation well, especially the lower
concentrations. Therefore, the malathion bioactivation rates were calculated from
Lineweaver Burk plots to determine differences in kinetic rates for rat and human
microsomes (interspecies) and differences with respect to age and variability in human
microsomes (intraspecies).
The Vmax values (presented as nmol/min/mg P) for malathion desulfuration ranged
from 3.44 to 59.24 for the human liver microsomes and 2.49 to 10.1 for the rat liver
microsomes (Table 1-2). The Kmapp values for malathion ranged from 0.18 mM to 18.60
mM for the human liver microsomes and 0.39 mM to 8.19 mM for the rat liver
microsomes (Table 1-2). The Vmax values were significantly higher for the human
microsomes than the rat microsomes (p ≤ 0.001); however, there were no significant
differences in the Kmapp values between the human and rat microsomes. The mean Vmax
values for both the humans and the rats were slightly higher for females than males but
did not reach significance at the p < 0.05 level. No significant differences were
determined for the Kmapp values between male and female rat microsomes or male and
female human microsomes. No age-related statistical differences (Pearson Product
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Moment Correlation) were determined among all of the human samples for Vmax or Kmapp.
In addition, the human liver microsomes were separated into two age groups, adults (> 12
years in age) and juveniles (< 12 years in age). No statistically significant differences in
Vmax or Kmapp were determined between the adults and juveniles.
The CaE activity of the individual human and rat liver microsomes was
determined using the substrate p-nitrophenyl valerate (Figures 5-6). Mean activities for
the rat liver microsomes were significantly higher than for the human liver microsomes
(p < 0.05). Activities ranged from 228 to 1296 (nmoles/min-1 mg P-1) and 5.4 to 36.4
(nmoles/min-1 mg P-1) for the rat and human liver microsomes, respectively. No
significant differences were determined between sexes for rats or humans. No agerelated differences were determined for the human liver microsomes when analyzed as a
complete data set.
Carboxylesterase mediated degradation of malathion was investigated by pre-incubating
parallel microsomal samples with or without a specific inhibitor for CaE, SCPP, followed
by the addition of a high concentration of malathion (200 µM). Malaoxon production, as
measured using an exogenous AChE trap, was increased for 25 of 27 human liver
microsomes and 9 of 12 rat liver microsomes pre-treated with the specific CaE inhibitor
(SCPP). Fold increases in malaoxon production with SCPP pre-treatment ranged from
1.1 to 3.9 for the human liver microsomes and 1.2 to 6.5 for the rat liver microsomes
(Table 3). Malaoxon production in rat and liver microsomes pre-treated with SCPP was
significantly (p < 0.01) higher than those pre-treated with EtOH vehicle only.
Carboxylesterase degradation of malaoxon was investigated by pre-incubating
parallel microsomal samples with or without a specific inhibitor for CaE, SCPP, followed
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by the addition of one of five concentrations of malaoxon (FCs, 1 µM-10 nM). As an
indirect measurement of CaE degradation of malaoxon, IC50s for the exogenous (electric
eel) AChE were calculated for comparison of the SCPP pre-treated samples to the EtOH
vehicle pre-treated samples, with a decrease in IC50 indicating more malaoxon available
to inhibit the AChE. IC50s for all rat liver microsomes were significantly decreased (2.0fold; p > 0.0001) with SCPP pre-treatment. IC50s for 25 of 27 human liver microsomes
were significantly decreased (2.3-fold; p > 0.0001) with SCPP pre-treatment (Table 4).
Finally, the proposed pathway of malaoxon hydrolysis by paraoxonase was
investigated using an indirect assay with an exogenous source of AChE (electric eel) as
measurement of remaining malaoxon following incubation with pooled rat or human liver
microsomes. CaE activity was inhibited using the specific inhibitor, SCPP, and parallel
samples with malaoxon were incubated with and without calcium (stimulates
paraoxonase activity) and with and without EDTA (inhibits paraoxonase activity). No
differences in AChE inhibition were determined indicating no paraoxonase mediated
hydrolysis of malaoxon was occurring.
Discussion
This study was designed to investigate the differences between rat and human
CYP-mediated metabolism of the organophosphate insecticide malathion. The kinetic
rates for malathion activation (desulfuration) were determined for rat and human liver
microsomes according to concepts developed by Leonor Michaelis and Maud Menten
(Michaelis-Menten kinetics). The widely used Michaelis-Menten equation depicts an
enzymatic reaction in which a substrate binds reversibly to an enzyme to form an
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enzyme-substrate complex, which then reacts irreversibly and generates a product and the
free enzyme (Michaelis and Menten, 1913; Goody and Johnson, 2011). This widely used
equation was used to calculate the maximum velocity (Vmax) and substrate affinity (Kmapp)
of malathion bioactivation (desulfuration) to its anticholinesterase metabolite, malaoxon.
The higher Vmax values for the human microsomes indicate human microsomal
CYPs are more efficient than rat microsomes in the bioactivation of malathion to
malaoxon. The Kmapp values for rat and human microsomes were not statistically
different indicating that the affinity for CYPs from both species was similar. Differences
in bioactivation (desulfuration) have been previously reported for several OPs (Sultatos,
1991; Chambers and Ma, 1994; 1995; Butler and Murray, 1997; Tang et al., 2001; Buratti
et al., 2003). Some studies have shown an increase in rates of bioactivation with age for
some OPs this could be a result of the calculation of data, whether it is normalized based
on protein levels or wet weight (per gram of tissue). Total protein levels have been
shown to increase with age, especially inducible proteins such as CYPs (Nims and Lubet,
1995; Atterberry et al., 2017). The representation of the data must be considered when
analyzing maturing levels of enzymes. The purchased human samples were standardized
by protein level (20 mg/ml) by the vendor; therefore, we adjusted the rat microsomes in a
similar manner for comparison purposes. No information was provided as to the amount
of tissue used to prepare the human hepatic microsomes, preventing the calculations on a
wet weight basis.
The CYP family consists of many different isoenzymes which catalyze many of
the same reactions but differ in their chemical properties or amino acid sequence
(Wilkinson, 1970; Guengerich, 1987). The isozyme content varies greatly in rodents and
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humans and given the differences in binding affinity (low, medium, and high) the overall
Kmapp and Vmax values can be quite different (Ma and Chambers, 1994; Tang et al., 2001;
Buratti et al., 2003, 2005). Rat and human hepatic microsomes have exhibited two
distinct straight lines for bioactivation of some OPs using Eadie-Hofstee plots, indicating
that two components catalyzed by different isoforms with different affinities are
involved. These different lines result in different kinetic parameters (Ma and Chambers,
1994; Buratti et al., 2005). In human liver microsomes, CYP2C19, 1A2, and 2B6 have
been shown to be very efficient in the bioactivation of malathion to malaoxon, while
CYP3A4 was shown to only be efficient at high malathion concentrations (Buratti et al.,
2005). CYP1A2 was reported to be the most efficient isozyme for malathion
bioactivation at lower malathion concentrations (more environmentally relevant levels)
(Buratti et al., 2005). The difference in total CYP concentration and isozyme content
may provide further variability between species. In addition, sex and age differences in
bioactivation of some OPs have been reported (Chambers et al., 1994; Tang et al., 2001).
These differences may be attributed to a difference in the total amount of CYP enzyme
present, differences in the proportion of isozymes, differences in the isozymes affinity for
the OP, or differences in normalization of the data.
The average Kmapp value for malathion desulfuration for adult male rats was 3.8
mM and 1.6 mM for adult female rats. The average Kmapp and Vmax values for malathion
desulfuration in human liver microsomes were 2.45 mM and 22.82 nmoles/min/mg P,
respectively, which was similar to published data of Buratti et al. (2005) for three
individual human liver microsomes. The affinity (Kmapp) of human and rat CYPs for OPs,
such as malathion, and the efficiency (Vmax) of bioactivation to the anticholinesterase
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metabolites can be useful in defining the differences in acute toxicity levels for OPs (Ma
and Chambers, 1994, 1995; Buratti et al., 2005) as well as constructing pharmacokinetic
models (Timchalk, 2002).
The variability in the human samples could be attributed to the variability in CYP
isozymes type and/or concentration present in the livers (Tang et al., 2001; Buratti et al.,
2003, 2005). Buratti et al. (2005) reported a greater than 200-fold inter-individual
variability in desulfuration rates for malathion among 16 human liver microsomes. In
addition, it has been well documented that the CYP isozymes may be induced or
inhibited by a variety of exogenous compounds (Guengerich, 1987; Nims and Lubet,
1995). The information supplied with the human samples did not include any
information concerning medications the individual may have been taking or the overall
health of the individuals, both of which could affect their metabolic capacities
(Guengerich, 1987). In addition, the preparation of the human liver microsomes was
performed by the vendor and the protocol used to prepare microsomes was not well
defined. The isozyme distribution within the liver has also been shown to be zonal;
therefore, the area of the liver used to prepare the microsomes may contribute to the
variability of the isozyme content and thus the interindividual bioactivation variability
(Buhler et al., 1992). Finally, 27 individual human microsomes is a relatively small
sample size and may not be representative of the total human population.
In addition to the variability of the bioactivation, the detoxication potential of the
rat and human microsomes were variable. The CaE variability among the human liver
microsomes was 18-fold and 5-fold for the rat liver microsomes. This was not unexpected
as many studies have shown variability in CaE activities in both laboratory animals and
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humans (Pope et al., 2005; Maxwell, 1992; Hosokawa et al., 1995; Atterberry et al.,
1997; Ross et al., 2012; Hinds et al., 2016; Moser et al., 2016). The increase in CaE
activity with age in rats has been well documented and has been suggested to play a
major role in the increase in susceptibility of immature animals to OP toxicity (Brodeur
and Dubois, 1963; Gagne and Brodeur, 1972; Benke and Murphy, 1975; Pope et al.,
1991; Atterberry et al., 1997). A study by Atterberry et al. (1997) demonstrated that
lower detoxication capacity (lower levels of CaE, paraoxonase, and CYP-mediated
dearylation) in the young animals contribute significantly to age-related differences in
sensitivity to some OPs (Atterberry et al., 1997). Some studies have reported an agerelated increase in CaE activity in human liver microsomes (Hosokawa et al., 1995; Pope
et al., 2005; Moser et al., 2016); however, these studies all consisted of very few
individuals and as reported in this study the intraspecies variability can be high. In
addition, sex differences in CaE activities have been reported in rats (Chambers and Carr,
1993). The sex and age differences in CaE activities reported in some studies may be
attributed to a difference in the total amount of enzyme present. Carboxylesterase levels
can be induced by variety of exogenous compounds increasing the variability of a
population (Zou et al., 2018).
Carboxylesterase, of which there is a finite number, is stoichiometrically inhibited
by OP oxons, thus this detoxication pathway is saturable. In the case of a high exposure
where the CaE is persistently phosphorylated by an OP oxon, the likelihood of the
inhibition of the target brain AChE and toxicity increases. In vivo studies in rats and
mice have used selective inhibitors of CaE, such as tri-o-tolyl phosphate (TOTP) and 2(o-cresyl)-4H-1,3,2-benzodioxaphosphorin-2-oxide (CBDP), to potentiate the toxicity of
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several OPs, including malathion (Casida, 1961; Dauterman and Main, 1966; Clement,
1984; Fonnum et al., 1985; Gupta and Dettbarn, 1987; Yang and Dettbarn, 1998). The
more recent development of CaE knockout (KO) and transgenic mouse models provide
an additional model to demonstrate the protective role of these detoxication enzymes.
Carboxylesterases are especially important for the detoxication of malathion
given its structure. The carboxylic esters in malathion make it susceptible to catalytic
hydrolysis by the promiscuous CaE to a non-toxic monocarboxylic acid metabolite that
can be excreted. The CYP-mediated bioactivation to malaoxon can occur
simultaneously. In addition, the malaoxon being produced can stoichiometrically inhibit
CaE reducing the amount of anticholinesterase metabolite but also reducing the amount
of CaE available to catalytically degrade malathion. This can be important in the case of
a high acute exposure or chronic exposure that saturates the CaE pool. These types of
exposures could result in increased toxicity to subsequent exposures of malathion or other
OPs prior to the de novo synthesis of new CaE. The in vitro studies conducted using the
specific CaE inhibitor, SCPP, exhibited the effectiveness of CaE to degrade both
malathion and malaoxon. Similar CaE-mediated detoxication of chlorpyrifos-oxon and
paraoxon has been reported for both rat liver and serum (Chambers and Carr, 1993,
Atterberry et al., 1997). Dauterman and Main (1966) synthesized homologs of malathion
and malaoxon and showed that increasing the carboxyalkyl chain length decreased the
potency towards CaE and in vivo toxicity as compared to malathion in rats, further
indicating the role of CaE in both malathion and malaoxon degradation. Impurities in
technical malathion and storage conditions can result in increased CaE and AChE
inhibition. Isomalathion, an impurity of malathion, is a more potent inhibitor of CaE and
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can increase the toxicity of malathion by several fold (Talcott et al., 1979). Finally, the
potential pathway of paraoxonase hydrolysis of malaoxon was determined to be
inconsequential. The lack of difference in eel AChE inhibition (trap) between
microsomes incubated with malaoxon with and without calcium indicates very little
contribution, if any, of paraoxonase in the degradation of malaoxon. Similar results
were reported by Moser et al. (2016).
Conclusion
The objective of this investigation was to determine the differences in
bioactivation of malathion to its anticholinesterase metabolite malaoxon between rats and
humans. Age-related differences in bioactivation of malathion were investigated using
individual human liver microsomes of various ages. In addition, the detoxication
potential of malathion and malaoxon were investigated using rat and human liver
microsomes. The efficiency of the bioactivation of malathion was higher for the human
liver microsomes than rats, but the apparent affinity for CYPs involved in the
bioactivation was not different between the species. There were no age-related
differences in the rates of bioactivation of malathion among the human liver microsomes;
however, the relatively small sample size may not be sufficient to determine this type of
difference for the human population. As expected, large variability was exhibited in CaE
activities for both rat and human liver microsomes. Carboxylesterase activities in rat
liver microsomes were higher than in the human microsomes. The detoxication of
malathion was confirmed to be primarily CaE-mediated in both species. The amount of
CaE-mediated degradation of both the parent insecticide, malathion, and the
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anticholinesterase metabolite, malaoxon, was substantial. Therefore, the
carboxylesterase-mediated detoxication of both malathion and malaoxon plays a major
role in the low mammalian toxicity of this widely used insecticide.
The data presented here are consistent with other data in the literature indicating
the importance of CaE in the detoxication of malathion. Other studies have investigated
differences in individual human liver microsomes; however, most of these contained very
small numbers of individual microsomes, did not include the wide age range that was
investigated here, and/or did not measure both activation and detoxication in the same
samples. Differences in the bioactivation of malathion may be more important in
individuals with low intrinsic CaE activity or in individuals that may have multiple
exposures to malathion or another OP that can reduce their CaE detoxication potential.
The interspecies and intraspecies differences in sensitivity of the target enzyme, AChE, to
malaoxon will be investigated in the next chapter. The metabolism of malathion is
complex and presents challenges to creating a pharmacokinetic model that will accurately
predict a toxicokinetic response for a given exposure. The interspecies and intraspecies
variability of the bioactivation and detoxication must be considered when assessing risk
to the human population from this widely used insecticide.
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Table 3.1

Kinetics of malathion desulfuration in rat hepatic microsomes.

Subject
#
1
2
3
4
5
6
Mean
SEM

Age
(days)
70
70
70
70
70
70
70
70

1
2
3
4
5
6
Mean
SEM

70
70
70
70
70
70
70
70

Sex
F
F
F
F
F
F
F
F

Kmapp
(mM)
3.00
1.47
0.76
1.46
2.30
1.69
1.66
0.34

Vmax
(nmoles/
min-1 mg P-1)
10.05
7.57
3.20
4.21
10.01
7.55
7.10
1.66

Vmax/
Kmapp
4.37
5.16
4.20
2.89
4.36
4.47
4.24
0.43

r2
0.992
0.987
0.926
0.903
0.993
0.930
0.960
0.02

M
M
M
M
M
M
M
M

6.91
2.17
2.25
2.93
8.19
0.39
3.81
1.76

7.37
4.04
5.84
2.49
5.73
5.85
5.22
0.98

1.07
1.86
2.59
0.85
0.70
14.88
3.66
3.20

0.987
0.947
0.984
0.922
0.851
0.974
0.940
0.03

Kinetic values (Vmax and Kmapp) for 12 adult rat liver microsomes of both sexes (6 each).
Data were calculated from Lineweaver Burk plots of means of 3 subsamples of eight
concentrations compared to vehicle controls. Differences in means between sexes were
determined using the Student’s t-test, with a level of p ≤ 0.05. No statistical difference
was determined for desulfuration with respect to sex.
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Table 3.2

Kinetics of malathion desulfuration in human hepatic microsomes.

Vendor
Sample #
354
57
410
25
393
177
115
355
Mean
SEM
845
268
395
270
825
322
852
551
346
792
215
59
485
133
236
36
420
201
203
Mean
SEM

Age
(years) Sex
0.04
F
2
F
11
F
30
F
30
F
45
F
48
F
71
F
29.6
F
14.3
F
0.08
0.33
0.42
0.42
0.92
1
2
2
3
4
6
9
10
17
17
37
42
58
75
15.1
12.7

M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M

Kmapp
(mM)
8.15
0.45
2.07
0.25
1.19
1.51
1.49
5.83
2.62
1.63

Vmax
(nmoles/
min-1 mg P-1)
46.42
10.30
26.68
10.88
48.16
22.82
17.75
46.26
28.66
9.30

Vmax/
Kmapp
5.70
23.15
12.91
43.87
40.47
15.11
11.91
7.93
20.13
8.42

r2
0.942
0.876
0.954
0.853
0.986
0.940
0.935
0.971
0.930
0.026

CYP
(nmoles/
mg P)
NA
0.32
0.69
0.29
0.54
0.51
0.22
0.60
0.45
0.10

0.36
18.60
4.79
0.66
0.44
5.36
0.33
0.33
0.28
0.76
2.10
0.18
0.38
1.80
0.54
1.15
2.29
4.72
0.24
2.38
2.47

19.92
59.24
32.84
5.69
13.66
24.71
3.44
3.45
19.60
9.10
13.21
4.23
21.43
15.40
12.19
25.12
30.99
57.90
14.85
20.37
9.26

55.64
3.19
6.86
8.57
31.26
4.61
10.53
10.54
69.75
12.04
6.29
24.17
56.25
8.56
22.79
21.84
13.53
12.27
62.13
23.20
12.39

0.987
0.948
0.964
0.887
0.930
0.880
0.868
0.865
0.947
0.971
0.938
0.956
0.979
0.970
0.897
0.904
0.979
0.960
0.897
0.930
0.024

0.34
0.38
NA
0.29
0.49
NA
0.30
0.31
NA
0.34
0.33
0.14
0.21
0.34
0.45
0.79
0.20
0.54
0.40
0.37
0.15

Kinetic values (Vmax and Kmapp) for 27 human liver microsomes of both sexes and various
ages. Data were calculated from Lineweaver Burk plots of means of 3 subsamples of
eight concentrations compared to vehicle controls. Differences in sexes were determined
using the Student’s t-test, with a level of p ≤ 0.05. No statistical difference was
determined for desulfuration with respect to sex. CYP activities were supplies by the
vendor. NA = data not available.
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Table 3.3

Indirect measurement of carboxylesterase degradation of malathion in rat
and human liver microsomes.

Rat

Human

Mean

SCPP
[malaoxon]
13454A

Ethanol
[malaoxon]
6657B

SEM

3326

2139

Mean

24128A

11985B

SEM

7650

2840

Fold
Change
2.0

2.0

Data expressed as malaoxon (pmoles/min-1 mg P-1produced from the CYP-mediated
bioactivation of malathion (200 µM) means ± SEM of 12 rat microsomes or 27 human
microsomes. Means within a species not followed by the same capital letter are
significantly different (p < 0.05) and were determined using the Student’s t-test. Higher
concentrations of malaoxon for the SCPP pre-treated samples indicate greater
degradation of malathion by carboxylesterase.
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Table 3.4

Indirect measurement of carboxylesterase degradation of malaoxon in rat
and human liver microsomes.

Pre-treatment
Liver
Microsome

Ethanol
SCPP
(AChE IC50) (AChE IC50)

Human

131 ± 33A

80 ± 29B

Rat

136 ± 25A

68 ± 9B

IC50s expressed as nM, for electric eel AChE, means ± SEM of 12 rat microsomes or 27
human microsomes. Means within a species not followed by the same capital letter are
significantly different (p < 0.05) and were determined using the Student’s t-test. Higher
AChE IC50 values for the ethanol vehicle pre-treated samples indicate less malaoxon
available to inhibit the exogenous AChE and indirectly estimate degradation by
carboxylesterase.
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Figure 3.1

Chemical structures of malathion and its active metabolite malaoxon.
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Figure 3.2

Proposed metabolic pathway of malathion in mammals. DMDTP =
dimethyldithiophosphate; DMTP = dimethylthiophosphate; CaE =
carboxylesterase.
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Figure 3.3
Standard curve for malaoxon inhibition of purified eel
acetylcholinesterase.
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Malathion Desulfuration by Human Liver Microsomes

1/malaoxon pmoles/min/mgP

0.00025

0.00020

0.00015

0.00010

0.00005

0.00000
0.000

0.002

0.004

0.006

0.008

0.010

[1/malaoxon uM]

Figure 3.4

Lineweaver Burk plots for inhibition kinetics
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0.012

Figure 3.5

Individual human hepatic microsomal carboxylesterase activities.

Carboxylesterase activities for individual human liver microsomes n = 27. Data are expressed as nmoles/min-1 mg P-1 and are
presented with increasing age in years. No statistical difference was determined for carboxylesterase with respect to age among the
27 samples, p ≤ 0.05.
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Figure 3.6

Rat hepatic microsomal carboxylesterase activities.

Carboxylesterase activities for individual adult rat liver microsomes n = 12. Data are
expressed as nmoles/min-1 mg P-1 and are presented by sex. Differences in means for
sexes were determined using the Student’s t-test, with a level of p ≤ 0.05. No statistical
difference was determined for carboxylesterase with respect to sex.
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CHAPTER IV
KINETICS OF ACETYLCHOLINESTERASE INHIBITION BY MALAOXON
Introduction
Malaoxon is the anticholinesterase metabolite of one of the most widely used
organophosphate (OP) insecticides, malathion (O,O-dimethyl dithiophosphate of diethyl
mercaptosuccinate; Figure 1). Malathion is a multiuse insecticide that is approved for use
in agriculture, both for crops and livestock, and in public health, for control of mosquitos
that transmit diseases such as west nile, malaria and zika (US EPA, 2009). Malathion has
a very low mammalian toxicity (male and female rat oral LD50s > 1000 mg/kg)
(Dauterman and Main, 1966; Terrell, 1979; Fisher, 1991; Meister, 1992); however,
malaoxon has been shown to be a relatively potent acetylcholinesterase inhibitor
(Dauterman and Main, 1966; Herzsprung, 1992).
The majority of the OP insecticides, such as malathion, must undergo
bioactivation (desulfuration) by cytochrome P450s (CYPs) to their active oxon
metabolites (e.g., malaoxon). The resulting oxons can inhibit the serine esterase,
acetylcholinesterase (AChE), in cholinergic synapses and neuromuscular junctions. The
inhibited AChE cannot inactivate the endogenous neurotransmitter ACh to terminate its
action as a neurotransmitter resulting in excess ACh and hyperstimulation of the
cholinergic system, followed by fatigue of ACh receptors (Mileson et al., 1998;
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Thompson and Richardson, 2004). Depending on the level of OP exposure, cholinergic
toxicity can occur followed by death, in cases of high level exposures (Taylor, 1990).
Acute toxicities from OP insecticides have been shown to vary among OPs and
species. Species differences in acute toxicity to OPs have been suggested to be due to
differences in the sensitivity of the target enzyme, acetylcholinesterase (AChE) (Murphy
et al., 1968). In addition, age-related differences in OP toxicities in animal models have
been demonstrated for many years (Benke and Murphy, 1975; Pope et al., 1991;
Mortensen et al., 1996; Moser et al., 1996; Atterberry et al., 1997). These types of
differences helped lead to the passing of the Food Quality Protection Act (FQPA) of
1996. FQPA mandated that pesticides with a common mechanism of toxic action were
required to undergo cumulative risk assessments and uncertainty factors were added for
interspecies and intraspecies variability (FQPA, 1996; Dourson et al., 1996; Mileson et
al., 1998). The interspecies uncertainty factor for the pharmacodynamics for OP
pesticides whose mechanism of toxic action is via the inhibition of AChE has been set to
a default value of 10x (US EPA, 2014). This uncertainty factor can be modified if there
is sufficient experimental data to support such a modification. In addition, there is an
additional uncertainty factor (10x) for intraspecies variation in AChE inhibition (Dourson
et al., 1996; US EPA, 2014). This in vitro study investigates both the interspecies (rat
and human) and intraspecies (among humans) variability of the sensitivity of AChE from
erythrocyte ghosts to the oxon metabolite of the OP insecticide malathion. These data
could be useful in modifications of uncertainty factors for malathion exposures.
Erythrocytes or red blood cells (RBCs) are responsible for the transport of oxygen
bound to hemoglobin molecules that are sequestered within the cells. Erythrocytes have
134

a high level of AChE activity which is subject to inhibition by OPs, such as malaoxon.
Maulet et al. (1984) determined erythrocyte AChE to be a glycoprotein and, in 1985, this
glycoprotein was shown to be located in the erythrocyte membrane (Ott, 1985).
Acetylcholinesterase molecules occur in three forms that differ only in their C-terminal
regions and are classified as R (readthrough), H (hydrophobic), or T (tail) (Massoulié et
al., 2002). Erythrocytes contain the H-form that exists as a dimer attached to the
membranes following posttranslational modification of the C-terminal region by
glycerophosphatidylinositol (Massoulié et al., 2002; Bartels et al., 1993).
Erythrocyte membrane AChE activity has been implicated as a biomarker of
membrane integrity with lower activity occurring in aged populations (Herz and Kaplan,
1973; Prall et al., 1998). In addition, sex differences have been determined with AChE
activity higher in females than in males (Prall et al., 1998; Hilário et al., 2003). Humans
with hemolytic anemia have been characterized by lower levels of erythrocyte AChE
(Prall et al., 1998). Erythrocyte AChE is also used as a biomarker of hypertension,
amyotrophic lateral sclerosis (ALS), Hirschsprung’s disease and glaucoma (Saldanha,
2017). In addition, erythrocyte AChE has been determined to be a marker of
inﬂammation (Saldanha, 2017) with the recruitment of leucocytes to the endothelial
vessel wall and in the production of pro-inﬂammatory cytokines in disease states (Das,
1997; Saldanha, 2017). Sargento et al. (2003) reported lower erythrocyte activity levels
in patients with diabetes mellitus. Acetylcholinesterase activity has also been shown to
affect NO efﬂux from erythrocytes through the activation of a protein kinase C pathway
(Saldanha, 2017). Erythrocyte AChE is used clinically as a diagnostic marker
(biomarker) for OP exposure (Prall et al., 1998; Bajgar, 2004) and because the catalytic
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domains are identical among tissues, erythrocyte AChE is used as surrogate biomarker of
brain AChE inhibition (Herkert et al., 2012; Chen et al., 1999)
Kinetic rates and equilibrium constants associated with enzyme/OP inhibitor
reactions can be measured using in vitro enzyme assays (Clothier et al., 1981; Johnson
and Wallace, 1987; Chambers and Carr, 1996; Coban et al., 2016). The mathematical
description of the inhibition of AChE by OP compounds has been described in depth by
Kitz and Wilson (1961), Aldridge and Reiner (1972), and applied by many others
(Clothier et al., 1981; Main, 1980; Richardson, 1992; Chambers and Carr, 1996; Johnson
and Wallace, 1987). These calculated pharmacodynamic parameters for the inhibition,
reactivation, and aging of AChE by an OP can be used in the construction and validation
of pharmacodynamic models used in the prediction of OP induced toxicity and
establishment of tolerance levels for OPs by regulatory agencies (Timchalk, 2001;
Dourson et al., 1996). The rate constants for OP inhibition of AChE can differ by orders
of magnitude depending on the differences in OP chemistries (Main, 1980). Therefore,
determining inhibition rate constants for individual OPs, such as malaoxon, provide
useful information that can help address differences in sensitivities to a OP both between
species and within species.
Materials and Methods
Chemicals
Malaoxon was supplied from FMC, Inc. Structures were confirmed by nuclear
magnetic resonance (NMR) at FMC and the Department of Chemistry at Mississippi
State University. Purity of malaoxon was determined to be greater than 98%. All other
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reagent grade chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) or
Thermo Fisher Scientific (Waltham, MA).
Animals
Adult male (6) and female (6) Sprague Dawley-derived rats (post-natal day 70,
PND 70; approximately 225-300 g) were purchased from Envigo, Inc. and housed in
AAALAC accredited facilities in the College of Veterinary Medicine at Mississippi State
University with temperature-controlled environments and 12 h dark-light cycle. Standard
lab chow and tap water were provided ad libitum. All animal procedures received prior
approval from the Mississippi State University Animal Care and Use Committee. Blood
from 6 rats of each sex was collected on ice and pooled for each of three replications for
erythrocyte ghost preparations.
Human Acetylcholinesterase
Human blood samples from individual healthy humans (age range 16-60 for
adults and 10-13 for juveniles) as well as cord blood samples were purchased from
Innovative Research (adults), BioreclamationIVT (juveniles), or Zen-Bio (cord blood).
Humans were of either sex and any race or ethnic group. All blood samples were
collected and shipped with cold packs overnight to Mississippi State University. The
samples were collected from 18 humans (9 adults, 5 juveniles and 4 cord bloods).
Preparation of Human and Rat Erythrocyte Ghosts
Erythrocyte ghosts (membrane preparations devoid of hemoglobin) were prepared
by centrifugation of whole blood anticoagulated with K2EDTA (3000 g for 10 min),
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plasma and buffy coat were carefully removed and packed erythrocytes were washed 3
times (1000 g centrifugation) using 2 volumes of 100 mM phosphate buffer (pH 7.4).
Erythrocytes were lysed using 20 volumes of hypotonic phosphate buffer (6.7 mM, pH
7.4) for 10 min on ice followed by centrifugation at 50,000 g for 30 min. The resulting
pellet was washed 3 times with 2 volumes of 100 mM phosphate buffer (pH 7.4) and
resuspended to original volume with 100 mM phosphate buffer (pH 7.4). The final ghost
preparations were light pink in color indicating a minimal amount of hemoglobin. Ghost
preparations from individual humans or rats were checked for AChE activity and diluted
to equivalent AChE activities (absorbance values, 0.5-0.6 AU in 5 min). The diluted
ghost preparations were aliquoted into individual cryogenic tubes and stored frozen at 80oC until assay. A previously conducted pilot study provided evidence that the human
ghost preparations did not lose appreciable AChE activity by freezing at -80oC for several
months but multiple freeze thaw cycles will decrease activity.
Determination of Erythrocyte AChE Inhibition Kinetics
Malaoxon inhibition kinetics studies were similar to previous kinetic studies from
our laboratory for anticholinesterases (Carr and Chambers,1996; Coban et al., 2016).
Inhibition of AChE in erythrocyte ghost preparations was conducted using a 96-well plate
format with a final reaction volume of 250 µl per well. A continuous spectrophotometric
assay was used to determine AChE activities (modification of Ellman et al., 1961) with
acetylthiocholine (ATCh) as the substrate and 5,5’-dithiobis(nitrobenzoic acid) (DTNB)
as the chromogen (Chambers et al., 1988; Carr and Chambers, 1996; Coban et al., 2016 ).
Range finding studies were conducted using a pooled erythrocyte ghost preparation to
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determine the effective concentration range of malaoxon that yielded about 10-90%
AChE inhibition. For each individual rat or human sample, 198 µl of diluted erythrocyte
ghost preparation was added to each well of a 96-well plate and warmed to 37oC in a
Jitterbug plate shaker for 5 min. To correct for non-enzymatic hydrolysis, 2 µl of eserine
sulfate (FC, 60 µM) was added to wells in the first column to serve as blank samples to
correct for non-AChE hydrolysis of substrate. The inhibition reaction was initiated by
pre-incubation of the erythrocyte ghost preparation with EtOH vehicle or eight
concentrations of malaoxon in EtOH. Additional wells were included that were devoid of
malaoxon or EtOH vehicle to compare to EtOH vehicle wells to monitor any unexpected
EtOH effects. Six pre-incubation periods were used (0-5 min at 1 min intervals).
Malaoxon was dissolved in dry EtOH and was added in a volume of 2 µl per well. The
inhibition reaction was terminated by addition of excess substrate, ATCh, which should
out-compete any unbound malaoxon for the active site of AChE. The AChE reaction was
initiated by the addition of a 40 µl mixture of ATCh and DTNB (to yield final
concentrations of 1 mM ATCh and 5 mM DTNB). For the 0-min time point, the
substrate/chromogen mixture was added simultaneously with malaoxon. Each reaction
was monitored by recording the absorbance at 412 nm for 8 min at 50 second intervals (to
yield 10 readings) and the velocity of each pre-incubation time was obtained for each
concentration and control. The linearity of the reaction was verified using the substrate
and chromogen alone to insure no substrate depletion (linearity was maintained beyond
10 min).
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Calculations for Malaoxon Inhibition Kinetic Constants
For the determination of enzyme inhibition kinetic constants for malaoxon, the
reaction of malaoxon with the enzyme was carried out without substrate,
acetylthiocholine, present. The assumption is that the enzyme and inhibitor bind
reversibly, followed quickly by the phosphorylation of the enzyme. The rate of
dissociation of the enzyme inhibitor complex is assumed to be faster than the rate of
phosphorylation. The persistence of the phosphorylation of the enzyme allows sufficient
time to measure the residual enzyme activity prior to reactivation. The enzyme-inhibitor
reaction can be quantified by the addition of substrate which out-competes the inhibitor
for the residual non-phosphorylated enzyme and the resulting product can be measured
spectrophotometrically over a given time. This procedure allows for the determination of
enzyme inhibition as a function of both time and concentration. The process of this
chemical reaction is described by the following equations:

Inhibition Equation

𝑘1
𝑘2
[𝐸] + [𝐼] ↔ [𝐸𝐼]𝑅 → [𝐸𝐼]𝐼
𝑘−1

Simplified Inhibition Equation

𝑘𝑖
[𝐸] + [𝐼] → [𝐸𝐼]

(1)

(2)

Where, ki = bimolecular rate constant and [EI]I = enzyme-inhibitor complex

According to this equation, [E] is the concentration of free enzyme, [I] is the
concentration of free inhibitor, [EI]R is the concentration of reversible enzyme-inhibitor
complex, [EI]I is the concentration of irreversibly phosphorylated enzyme-inhibitor
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complex. According to a method described by Kitz and Wilson (1962), kinetic constants
can be calculated for this reaction including: the bimolecular rate constant, ki , the
phosphorylation constant of the enzyme, kp, and the dissociation constant, KI, for the
enzyme-inhibitor complex. For each malaoxon incubation time, the enzyme (AChE)
velocity following inhibition ([E] t) was divided by the original uninhibited velocity
([E] o) to obtain the fraction of AChE velocity remaining ([E] t/[E] o). The “apparent” rate
of AChE phosphorylation (slope = -kapp) for each concentration was calculated by linear
regression of the natural log (ln) of the [E] t/[E] o as a function of time (Figure 2). Using a
double reciprocal plot (Figure 3) of 1/kapp versus 1/[I], (SigmaPlot 13 software), the
constants ki (slope = 1/ki), kp (y intercept = 1/kp), and KI (x intercept= -1/KI) were
calculated (Wilkinson, 1961; Ritchie and Prvan, 1996). The data suggest that inhibition
of AChE follows pseudo-first-order kinetics as described by Michaelis-Menten
(Michaelis and Menten, 1913; Goody and Johnson, 2011) and better fit a hyperbolic
curve. For comparison, the data were plotted as kapp versus [I] which yielded a
hyperbola (Figure 4). The data were fit to the equation for a hyperbola (y = ax/(b + x))
where y = kapp and x = [I] and the equation was solved for a and b (a = kp and b = KI)
(Wilkinson, 1961; Ritchie and Prvan, 1996). The data from the double reciprocal plot
and the hyperbolic plot should be similar. In addition, IC50s were calculated for the last
time point (5 min) as a comparison because IC50s are determined from the middle (50%)
of an inhibition curve which should be the most accurate point (errors are greater at the
upper and lower ends of inhibition curves). Statistical differences between mean kinetic
values between rats and humans and between sexes within a species were determined by
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Student’s t-test. Statistical differences among human ghost preparations with respect to
age were determined by linear regression.
Results
The erythrocyte ghost preparations were determined to be stable at -80oC. A final
concentration range for malaoxon of 3.16 x10-7 M to 1.77 x10-5 M was determined to
produce an inhibition range of about 10% to 90% of AChE in erythrocyte ghost
preparations. This concentration range was used for each of the 24 ghost preparations (6
rats and 18 humans). Non-enzymatic hydrolysis of ATCh was determined to be minimal.
The kinetic constants obtained for each individual human or rat erythrocyte ghost
preparation incubated with increasing concentrations of malaoxon were initially
calculated by analysis of a double reciprocal plot (e.g., Figure 3) for each erythrocyte
ghost preparation with a mean r2 for the lines of 0.947 for humans and 0.973 for rats
(Table 1-2). Subsequently, kinetic constants were calculated from a hyperbolic plot (e.g.,
Figure 4) for malaoxon for each individual human or rat erythrocyte ghost preparation
with a mean r2 for the lines of 0.968 for humans and 0.992 for rats (Table 3-4).
The bimolecular rate constant (ki) for malaoxon calculated from the double
reciprocal plots from the 18 individual human erythrocyte ghost preparations ranged from
0.154 x105 to 3.722 x105 L∙mol-1∙min-1 , while the ki calculated from the double reciprocal
plots for the rat erythrocyte ghost preparations ranged from 0.684 x105 to 1.780 x105
L∙mol-1∙min-1 for malaoxon. The phosphorylation constant (kp) calculated from the
double reciprocal plots for the 18 human erythrocyte ghost preparations ranged from
0.1408 to 1.061 min-1. For the rat erythrocyte ghost preparations, the kp calculated from
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the double reciprocal plots ranged from 0.182 to 29.58 min-1. The dissociation constant
(KI) calculated from the double reciprocal plots for the 18 human erythrocyte ghost
preparations ranged from 0.900 x10-6 to 12.70 x10-6 mol∙L-1, while the KI calculated from
double reciprocal plots for the rat samples ranged from 2.660 x 10-6 to 348.0 x 10-6 mol∙L1

(Table 1-2).
For comparison, the same data were fit to the more accurate hyperbolic equation.

The kis calculated by hyperbolic plot analysis using erythrocyte ghost preparations from
the 18 individual human samples ranged from 0.078 x105 to 2.196 x105 L∙mol-1∙min-1 for
malaoxon. In rats, the ki calculated from the hyperbolic plots ranged from 0.419 x105 to
1.173 x 105 L∙mol-1∙min-1. The kp calculated from the hyperbolic plots for the erythrocyte
ghost preparations from the 18 individual human samples ranged from 0.259 to 1.581
min-1. For the rat erythrocyte ghost preparations, kp calculated from the hyperbolic plots
ranged from 0.555 to 13.73 min-1. Finally, the KI calculated from the hyperbolic plots for
the erythrocyte ghost preparations from the 18 individual human samples ranged from
2.032 x10-6 to 15.88 x 10-6 mol∙L-1 and 3.946 x10-6 to 23.94 x10-6 mol∙L-1 for the rat
erythrocyte ghost preparations (Table 3-4).
Kinetic rate constants were compared between the two methods of data
representation (a linear double reciprocal plot or hyperbolic plot) and were not
determined to be significantly different from each other for the human or rat erythrocyte
ghost preparations (p < 0.05). Therefore, the results from this point forward will refer to
the kinetic constants derived from more accurate hyperbolic analyses. The mean
bimolecular rate constant (ki), calculated from the hyperbolic plots, for the human
erythrocyte ghost preparations was 1.07 x 105 L∙mol-1∙min-1, while the mean ki for the rat
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erythrocyte ghost preparations was 0.813 x 105 L∙mol-1∙min-1. The mean phosphorylation
constant (kp) calculated from the hyperbolic plot for the human erythrocyte ghost
preparations was 0.594 min-1, while the mean kp for the rat erythrocyte ghost preparations
was 0.830 min-1. The mean dissociation constant (kI), calculated from the hyperbolic
plots, for the human erythrocyte ghost preparations was 5.75 x10-6 mol∙L-1, while the
mean kp for the rat erythrocyte ghost preparations was 1.08 x10-6 mol∙L-1.
Statistical differences were not found between the human and rat kinetic rate
constants (p < 0.05). In addition, no statistical differences were determined for any of the
three rate constants between sexes for the individual humans or rat erythrocyte ghost
preparations. No age-related differences were determined for the three kinetic rate
constants for the 18 individual human erythrocyte ghost preparations, when statistically
analyzed as a complete population (linear regression) or when separated and compared as
three separate age groups (cord blood, juveniles, and adults). Finally, no interspecies or
intraspecies were found using IC50s from the five minute malaoxon incubation and the
IC50s correlated with the bimolecular rate constants (ki).
Discussion
The kinetic data for malaoxon was calculated by the methods described by Kitz
and Wilson (1962). The kinetic constants derived from these methods for malaoxon
included: the bimolecular rate constant (ki), phosphorylation constant (kp), and
dissociation constant (KI). Initially, kinetic constants were calculated from a double
reciprocal plot (Lineweaver Burk) as this has been widely used for many years to
calculate enzyme kinetic constants (Wilkinson, 1961; Kitz and Wilson, 1962; Johnson
144

and Wallace, 1987; Ma and Chambers, 1995; Ritchie and Prvan, 1996; Coban et al.,
2016).

The Lineweaver Burk plots rely on transformed data which has been shown to

magnify errors, especially at the lower and upper ends of the curve (Ritchie and Prvan,
1996). For comparison, data were fit to the equation for a hyperbola, which is the
preferred form (Wilkinson, 1961; Ritchie and Prvan, 1996).
Acetylcholinesterase in mammals has been determined to be encoded by a single
gene and the catalytic domains of the different molecular forms of AChE expressed in
tissues of rat and humans have been determined to be identical (Taylor et al., 1993;
Massoulié et al., 2008). The amino acid sequences of the catalytic domains of brain and
erythrocyte AChE are identical within a given mammalian species (human or rat)
(Basova and Rozengart, 2009; Carr and Ollis, 2009; Cygler et al., 1993; Herkert et al.,
2012; Uniprot, 2017a,b; Wiesner et al., 2007). With catalytic domains for AChE
molecules being identical, erythrocyte AChE activity and pharmacodynamic parameters
have routinely been used as a surrogate for brain AChE activity and pharmacodynamic
parameters. Rat erythrocyte AChE pharmacodynamic parameters have also been used as
a surrogate for human AChE pharmacodynamic parameters. The catalytic domains of rat
and human erythrocyte AChE have high sequence homology (88.6%) and therefore, a
high degree of predicted 3D structural homology (Konagurthu et al., 2006; Massoulié et
al., 2008; Uniprot 2017a,b). This gives rise to the hypothesis that rat and human AChE
would be expected to interact similarly with OP inhibitors. The data from this study
support this hypothesis that rat and human AChE are very similar in structure and
function with no statistical differences determined in the erythrocyte ghost AChE
inhibition kinetic constants between the two species. In addition, given the homology of
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the catalytic site of AChE within tissues of the same species, one would not expect
significant intrahuman variability in AChE inhibition from an OP. Variability in AChE
activity with age has been reported in the literature, with some studies reporting increases
or decreases but the majority reported no differences (Ecobichon and Stephens, 1972;
Ramenjak, 2009). However, the differences in activity could be a result of the
methodology of determining activity; i.e., is activity representing the total numbers of
molecules or catalytic efficiency of a given molecule. Animal studies have indicated a
decrease in sensitivity of AChE and toxicity to OP insecticides with increasing age
(Benke and Murphy, 1975; Pope et al., 1991; Mortensen et al., 1996; Atterberry et al.,
1997). However, these differences can be attributed to age related differences in
pharmacokinetics and maturation in the OP detoxication enzymes, such as
carboxylesterase and paraoxonase (Maxwell, 1992; Atterberry et al., 1997; Mortensen et
al., 1998; Vidair, 2004).
The experimental data for malaoxon from this study support this hypothesis as no
significant differences in inhibition kinetic constants were exhibited among the 18 human
erythrocyte ghost preparations. The selection of 18 subjects represented a range of age as
well as both sexes and several ethnicities. This is still a relatively small sample size and
therein lies the concern of the sufficiency of 18 human samples to represent intrahuman
variability for the whole population. However, the lack of differences in any of the
inhibition rate constants combined with the complete homology of the catalytic site of
AChE within a species suggests there is relatively small variability among the human
population.
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There have been differences in AChE activity within a species (intraspecies)
reported in both rats and humans (Herz and Kaplan, 1973) which most likely results from
differences in AChE concentration. The rate of inhibition of AChE for an OP would be
expected to be proportional to the AChE mass and is determined by the activity level and
the turnover rate (de novo synthesis). At environmentally relevant OP exposures levels
where activity levels are not completely inhibited, the activity level probably does not
greatly affect the percent inhibition level. Finally, the sites of post-translational
modifications of AChE are peripheral to the catalytic site and have very little effect on
the activity of AChE (Massoulié et al., 2008). With the lack of post translational
modifications in the catalytic domain of AChE, genetic mutations within the catalytic
domain would likely be the only factor to alter the pharmacodynamic parameters of the
enzyme; however, these mutations are extremely rare (Lockridge et al., 2016).
The structure of OPs can affect the inhibitory potency for the target enzyme,
AChE, and result in a wide range of toxicities (Main, 1980). Studies by Wang and
Murphy (1982) demonstrated that differences in affinity and phosphorylation rates for
OPs can result in differences in inhibition of AChE. Bimolecular rate constants (kis) for
the diethyl phosphates chlorpyrifos-oxon and paraoxon are different although the
structures only differ in their leaving groups. Similar differences were reported with
other OPs including insecticides, nerve agents and nerve agent surrogates (Bošković,
1968; Herzsprung et al., 1992; Coban et al., 2016). The differences in rates of
phosphorylation (kp) can contribute to the inhibitory potency of an OP, although these
differences are suggested to be minimal while the association with the inhibitor (KI) is
suggested to be more important in inhibitor potency (ki) (Carr and Chambers, 1996;
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Wang and Murphy, 1982; Kemp and Wallace 1990). In addition, different potencies
between OPs may be due to interactions at the anionic site that can produce
conformational changes in the tertiary structure of the enzyme resulting in preferential
binding of one inhibitor over another (Wallace, 1992). Finally, other factors can
influence the potency of an OP for AChE such as pH and temperature (Main and Iverson,
1966; Carr and Chambers, 1996). All these factors must be considered when comparing
interspecies and intraspecies in vitro potency values for AChE.
Conclusions
The kinetic constants derived for malaoxon may be used in pharmacodynamic
models to address the toxicodynamics of malathion. The data determined in this study
for malaoxon using erythrocyte ghost preparations are useful as a biomarker for the
target, brain AChE, especially with the evidence that erythrocyte and brain AChE are the
same gene product with identical catalytic domains. The kinetic parameters obtained for
rats and humans from erythrocyte ghost preparations are intended to help address the
interspecies uncertainty in risk assessment of malathion. Similarly, the kinetic
parameters obtained from the individual human erythrocyte ghost preparations are
intended to address the intraspecies uncertainty factors in the risk assessment of
malathion. Malaoxon was shown to be a relatively potent inhibitor of AChE, but no
significant differences were determined in the interspecies or intraspecies sensitivity of
erythrocyte AChE to malaoxon, indicating the low mammalian toxicity for the parent
insecticide, malathion, most likely results from the organisms’ detoxication capacity.
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Table 4.1

Sample
Human 1
Human 2
Human 3
Human 4
Human 5
Human 6
Human 7
Human 8
Human 9
Human 10
Human 11
Human 12
Human 13
Human 14
Human 15
Human 16
Human 17
Human 18

Inhibition kinetic constants for malaoxon in erythrocyte “ghosts” from
humans (double reciprocal analysis).
Age
(years)
0.691
0.698
0.70
0.73
10
10
10
11
13
16
23
27
30
31
35
46
51
60

Sex
M
F
M
F
F
M
F
F
M
F
M
F
F
M
F
M
F
M

ki
(L∙mol-1∙min-1)
0.359 x105
0.612 x105
0.837 x105
2.560 x105
1.378 x105
1.142 x105
0.194 x105
0.646 x105
0.994 x105
1.650 x105
0.154 x105
3.722 x105
1.299 x105
1.252 x105
0.735 x105
1.457 x105
1.560 x105
1.273 x105

kp
(min-1)
0.1622
0.1408
0.6153
0.3987
0.7497
0.3349
0.1939
0.8319
0.4168
0.9378
0.1971
0.3212
0.5410
0.3231
0.8000
0.5485
1.061
0.5327

KI
(mol∙L-1)
4.50 x10-6
2.30 x10-6
7.35 x10-6
1.56 x10-6
5.44 x10-6
2.93 x10-6
10.0 x10-6
12.9 x10-6
4.19 x10-6
5.60 x10-6
12.7 x10-6
0.90 x10-6
4.16 x10-6
2.58 x10-6
10.9 x10-6
3.77 x10-6
6.80 x10-6
4.20 x10-6

r2
0.867
0.835
0.983
0.857
0.962
0.995
0.942
0.996
0.956
0.985
0.958
0.936
0.988
0.836
0.979
0.995
0.982
0.999

IC50s
(nM)
293
69
393
295
555
341
90
467
129
804
50
520
509
279
372
560
536
482

Kinetic constants calculated from double reciprocal plots for 18 human erythrocyte ghost
preparations. Data for ki = bimolecular rate constant (L∙mol-1∙min-1), kp =
phosphorylation constant (min-1), and KI = dissociation constant (mol∙L-1). IC50s
calculated from the 5 min time point. IC50 data expressed as nM.
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Table 4.2

Sample
Rat 1
Rat 2
Rat 3
Rat 4
Rat 5
Rat 6

Inhibition kinetic constants for malaoxon in erythrocyte “ghosts” from rats
(double reciprocal analysis).

Age
(days)
70
70
70
70
70
70

Sex
M
M
M
F
F
F

ki
(L∙mol-1∙min-1)
1.780 x105
0.991 x105
1.117 x105
0.850 x105
0.480 x105
0.684 x105

kp
(min-1)
0.6729
1.132
0.8591
29.580
0.7250
0.1820

KI
(mol∙L-1)
3.80 x10-6
11.4 x10-6
7.69 x10-6
348 x10-6
15.1 x10-6
2.66 x10-6

r2
0.990
0.991
0.966
0.980
0.974
0.936

IC50s
(nM)
608
404
392
417
105
234

Kinetic constants calculated from double reciprocal plots for 6 pools of rat erythrocyte
ghost preparations (3 males and 3 females). Data for ki = bimolecular rate constant
(L∙mol-1∙min-1), kp = phosphorylation constant (min-1), and KI = dissociation constant
(mol∙L-1). IC50s calculated from the 5 min time point. IC50 data expressed as nM.
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Table 4.3

Sample
Human 1
Human 2
Human 3
Human 4
Human 5
Human 6
Human 7
Human 8
Human 9
Human 10
Human 11
Human 12
Human 13
Human 14
Human 15
Human 16
Human 17
Human 18

Inhibition kinetic constants for malaoxon in erythrocyte “ghosts” from
humans (hyperbolic analysis).

Age
(years)
0.691
0.698
0.70
0.73
10
10
10
11
13
16
23
27
30
31
35
46
51
60

Sex
M
F
M
F
F
M
F
F
M
F
M
F
F
M
F
M
F
M

ki
(L∙mol-1∙min-1)
0.241 x105
0.353 x105
1.252 x105
1.736 x105
1.798 x105
0.880 x105
0.229 x105
0.943 x105
0.570 x105
2.196 x105
0.078 x105
1.736 x105
1.072 x105
0.772 x105
1.188 x105
1.363 x105
1.670 x105
1.195 x105

kp
(min-1)
0.2588
0.3368
0.4039
0.4300
0.5433
0.6674
0.1150
0.4094
0.9057
0.7375
1.581
0.5131
0.7547
0.7203
0.3306
0.6756
0.7601
0.5536

KI
(mol∙L-1)
10.75 x10-6
9.54 x10-6
3.23 x10-6
2.42 x10-6
3.02 x10-6
7.85 x10-6
5.01 x10-6
4.30 x10-6
15.9 x10-6
3.36 x10-6
2.03 x10-6
2.96 x10-6
7.04 x10-6
9.33 x10-6
2.78 x10-6
4.96 x10-6
4.55 x10-6
4.48 x10-6

r2
0.971
0.978
0.963
0.831
0.980
0.992
0.978
0.987
0.960
0.984
0.958
0.912
0.994
0.983
0.979
0.998
0.982
0.997

Kinetic constants calculated from hyperbolic plots for 18 human erythrocyte ghost
preparations. Data for ki = bimolecular rate constant (L∙mol-1∙min-1), kp =
phosphorylation constant (min-1), and KI = dissociation constant (mol∙L-1). IC50s
calculated from the 5 min time point. IC50 data expressed as nM.
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IC50s
(nM)
293
69
393
295
555
341
90
467
129
804
50
520
509
279
372
560
536
482

Table 4.4

Sample
Rat 1
Rat 2
Rat 3
Rat 4
Rat 5
Rat 6

Inhibition kinetic constants for malaoxon in erythrocyte “ghosts” adult rats
(hyperbolic analysis).

Age
(days)
70
70
70
70
70
70

Sex
M
M
M
F
F
F

ki
(L∙mol-1∙min-1)
0.687 x105
1.173 x105
1.126 x105
0.897 x105
0.574 x105
0.419 x105

kp
(min-1)
0.6842
0.6494
0.6652
1.056
1.373
0.5548

KI
(mol∙L-1)
3.95 x10-6
5.54 x10-6
5.91 x10-6
12.0 x10-6
23.9 x10-6
13.3 x10-6

IC50s

r2
0.994
0.998
0.993
0.990
0.993
0.987

(nM)
608
404
392
417
105
234

Kinetic constants calculated from hyperbolic plots for 6 pools of rat erythrocyte ghost
preparations (3 males and 3 females). Data for ki = bimolecular rate constant (L∙mol1
∙min-1), kp = phosphorylation constant (min-1), and KI = dissociation constant (mol∙L-1).
IC50s calculated from the 5 min time point. IC50 data expressed as nM.
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Figure 4.1

Chemical structures of malathion and its active metabolite
malaoxon.
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Figure 4.2

Inhibition curves for eight concentrations of malaoxon over six
incubation periods.

Representative plot of -ln(% AChE activity) vs. time (min). One of 18 plots for human
erythrocyte AChE incubated with 8 increasing concentrations of malaoxon compared to
EtOH vehicle controls. Individual r2 were determined for each line.
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Figure 4.3

Double-reciprocal plot for malaoxon inhibition of erythrocyte
acetylcholinesterase.

Representative double-reciprocal plot of 1/malaoxon concentration (M) vs. 1/kapp. One of
18 hyperbolic plots for human erythrocyte AChE incubated with 8 increasing
concentrations of malaoxon compared to EtOH vehicle controls.
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Figure 4.4

Hyperbolic plot for malaoxon inhibition of erythrocyte
acetylcholinesterase.

Representative hyperbolic plot of malaoxon concentration (M) vs. kapp. One of 18
hyperbolic plots for human erythrocyte AChE incubated with 8 increasing concentrations
of malaoxon compared to EtOH vehicle controls.
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CHAPTER V
CONCLUSION
Although the usage of organophosphate (OP) insecticides has declined over the
last decade as insect resistance has developed and new insecticidal chemistries have been
discovered with different modes of action, exposures to OPs are still a concern in the US
and around the world. The wide variety of applications from agricultural to residential
for OPs increases the potential of exposure to non-target species, such as animals and
humans. Of particular concern is exposure to children, which are more susceptible to
toxic insult from OPs because of their developing nervous systems as well as lower
detoxication capacities. The passage of the Food Quality Protection Act (FQPA) in 1996
required additional consideration for the susceptibility of infants and children to
pesticides. Under FQPA, the addition of 10x uncertainty (safety) factors for extrapolation
of animal studies to humans (interspecies) and the protection of sensitive populations
(intraspecies) was mandated unless sufficient experimental and epidemiological data
allowed for the reduction of the safety factors. In addition, pesticides with a common
mechanism of toxicity, such as the OPs, were required to undergo a cumulative risk
assessment which addresses the risk associated with total exposure to multiple OPs from
multiple routes. The reassessment of risk for all the registered OPs was a massive
undertaking that lasted over a decade and required many additional in vitro and in vivo
studies. Although the cumulative risk assessment for the OPs has been completed,
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reassessments of individual compounds still occur when new data with toxicological
implications is produced.
This research investigated the differences in activation and detoxication of OP
insecticides in both rat and human tissues, with an overall hypothesis that the age-related
differences in acute toxicity for many OPs are primarily the result of the maturation of
detoxication enzymes and less likely the result of differences in bioactivation and
sensitivity of the target enzyme, AChE, to the OP.
The first study was designed to determine age-related differences in sensitivity of
the target enzyme AChE to a structurally diverse group of OPs in vitro. In addition, the
age-related differences in sensitivity of OP detoxication enzymes, carboxylesterase (CaE)
and butyrylcholinesterase, to the same diverse group of OPs was determined in vitro to
assess the potential protection these enzymes may provide to the target enzyme AChE for
a given OP structure. Log inhibitor concentration-logit percent inhibition regression lines
were used to determine the IC50 concentrations for AChE, BChE and CaE in several
tissues from neonatal, juvenile and adult male rats. The twelve OP compounds
investigated displayed a wide range of inhibitory potential, as evidenced by their IC50s,
toward the target enzyme, AChE, as well as non-target detoxication enzymes, BChE and
CaE, ranging several orders of magnitude. Although IC50s do not provide as much
information about an inhibitor as kinetic rate constants, they require less tissue, time and
expense to determine and they provide a good way to compare potencies among
compounds with similar chemistries in different tissues and species. The di-ethyl
phosphate insecticidal OPs, such as chlorpyrifos-oxon and paraoxon, were generally
more potent inhibitors of AChE than the di-methyl phosphate insecticidal OPs. This is in
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contrast to the acute toxicities of some of the parent insecticides. The detoxication
enzymes, CaE and BChE, were stoichiometrically inhibited at lower concentration of the
diethyl phosphates (insecticidal) than the dimethyl phosphate inhibitors which could
account for the greater acute toxicity for some of the dimethyl OPs. In vitro studies, such
as these, can provide insights into the age-related differences in the acute toxicity
reported for many OPs from in vivo challenges. In vivo challenges of OPs are ultimately
needed to address the differences in toxicity for OPs differing in structure; however, in
vitro studies such as the one reported here can provide information for the biochemical
pathways that can then be used in developing predictive models that once validated can
help address differences in species and age-related toxicities. Ultimately, these types of
predictive models can reduce or replace the number of in vivo studies necessary to
address risk to humans.
One of the most heavily used OPs still on the market is the
phosphorothionothiolate insecticide malathion. The use of malathion in agriculture, such
as the eradication of cotton boll weevil, and in public health, control of vector-borne
(mosquito) diseases, increases the potential of exposure to humans. The popularity of
malathion within the insecticide marketplace stems from its good insecticidal properties
and its low mammalian toxicity (rat oral LD50 > 1 g/kg). Malathion requires cytochrome
P450 (CYP) bioactivation (desulfuration) to its anticholinesterase metabolite, malaoxon.
Malathion and malaoxon can both be efficiently degraded (detoxified) by CaE. The CaEmediated degradation of malathion is catalytic, while the detoxication of malaoxon is
stoichiometric, making malathion fairly unique among the OPs. The interspecies and
intraspecies differences in bioactivation and detoxication of malathion were investigated
165

in the second part of this study using hepatic microsomes obtained from 6 male and 6
female adult rats and 27 humans of both sexes and various ages. The kinetics of
malathion desulfuration in rat and human hepatic microsomes were determined using
standard Michaelis-Menten equations. The efficiency of the bioactivation of malathion
was higher for the human liver microsomes than rats, but the affinity of CYPs for
malathion was not different between rats and humans. There were no age-related
differences in the rates of malathion desulfuration among the human hepatic microsomes;
however, the sample size may not be sufficient to determine an age-related difference for
the human population. The detoxication of malathion by CaEs was investigated as the
primary pathway in the detoxication of malathion in both rats and humans. CaE activities
were variable in both rat and human hepatic microsomes, with CaE activities in rat
hepatic microsomes higher than in the human hepatic microsomes. The catalytic
degradation of malathion and the stoichiometric detoxication of malaoxon by hepatic
microsomal CaE both contribute substantially to the reduction of circulating OP
following exposure. This reduces the amount of OP available to inhibit the target
enzyme, AChE, and is largely responsible for the low mammalian acute toxicity for
malathion. The data in this study are consistent with data from the literature indicating
the importance of CaE in the detoxication of malathion. Carboxylesterase concentrations
and CYP isozyme content have been shown to vary among humans as well as be
inducible or inhibited by a variety of xenobiotics, which could result in differences in
bioactivation and detoxication of malathion and toxicity. In addition, multiple exposures
to malathion or another potent OP could reduce a person’s CaE detoxication capacity,
thus increasing malathion toxicity. The kinetic rates for bioactivation as well as the
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detoxication pathways reported here can be used in the development of physiologicallybased pharmacokinetic and pharmacodynamic models (PBPK/PD). These models, once
validated can be used to refine uncertainty factors and tolerance levels of humans to OPs,
such as malathion.
In the final part of this study, the interspecies and intraspecies differences in
sensitivity of the target enzyme, acetylcholinesterase, to malaoxon inhibition were
investigated. Erythrocyte AChE derived from pools of 6 rats of both sexes (3 male pools
and 3 female pools) and 18 individual humans from both sexes and a variety of ages and
ethnicities was used to determine kinetic constants for the inhibition of AChE by
malaoxon. Kinetic constants calculated from AChE inhibition measured over time with
increasing concentrations of malaoxon included the bimolecular rate constant (ki),
phosphorylation constant (kp), and dissociation constant (KI). Kinetic analyses provide a
quantitative means to evaluate the effects (potency) of inhibitors on enzymes. In
addition, kinetic analyses allow the quantitation of differences between the same enzyme
in different species or tissues from the same species. Acetylcholinesterase in mammals is
encoded by a single gene that has identical catalytic domains; therefore, it was
hypothesized that there would be no differences in interspecies and intraspecies
malaoxon inhibition of AChE. The values for ki, kp, or KI were not significantly different
between rats and humans, this is important with the inability to test OPs in humans
because of ethical limitations. Regulatory agencies are limited to using pharmacokinetic
data from humans and toxicokinetic/dynamic data from animal models for risk
assessments. In addition to the lack of species differences in AChE inhibition kinetic
values, no significant differences were determined for kinetic values between sexes for
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rats or humans. Finally, no age-related statistical differences were determined for any of
the kinetic values. Given the literature evidence that erythrocyte and brain AChE are the
same gene product with identical catalytic domains, the kinetic data determined in this
study for malaoxon using erythrocyte ghost AChE preparations could be used as a
surrogate for the target, brain AChE. The kinetic constants derived for malaoxon may be
used in pharmacodynamic models to address the toxicodynamics of malathion.
Malaoxon was shown to be a relatively potent inhibitor of AChE, but no significant
differences were determined in the interspecies or intraspecies sensitivity of erythrocyte
AChE to malaoxon, indicating the low mammalian toxicity for the parent insecticide,
malathion, most likely results from the organisms’ detoxication capacity. The absence of
meaningful interspecies and intraspecies differences in erythrocyte AChE inhibition
could provide sufficient evidence for the reduction of safety factors for malathion.
This study suggests that species and age-related differences in acute toxicities for
OPs are primarily due to differences in detoxication capacities of mammals and less
likely due to differences in bioactivation of OPs to their oxon metabolites and sensitivity
of the target enzyme, AChE, to those oxon metabolites. Additionally, bioactivation,
detoxication and inhibitory potential of OPs is largely dependent on the chemical
structures of the OP. Future studies using software to predict structure activity
relationships for OPs with human CYPs and CaEs could provide additional information
aiding in predicting toxicity based on chemical structure. In vivo studies using knockout
animal models for CaE could provide information on the role CaE plays in the
detoxication of OPs. Finally, variability of bioactivation and detoxication enzymes in the
human population must be investigated to ensure protection of sensitive populations.
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